- Genome-wide analysis in 756,646 individuals provides first genetic evidence 1
- that ACE2 expression influences COVID-19 risk and yields genetic risk scores 2
- predictive of severe disease 3
- 5 J. E. Horowitz^{1†}, J. A. Kosmicki^{1†}, A. Damask^{1†}, D. Sharma¹, G. H. L. Roberts², A. E. Justice³, N.
- Banerjee¹, M. V. Coignet², A. Yadav¹, J. B. Leader³, A. Marcketta¹, D. S. Park², R. Lanche¹, E. 6
- 7 Maxwell¹, S. C. Knight², X. Bai¹, H. Guturu², D. Sun¹, A. Baltzell², F. S. P. Kury¹, J. D. Backman¹,
- 8 A. R. Girshick², C. O'Dushlaine¹, S. R. McCurdy², R. Partha², A. J. Mansfield¹, D. A. Turissini²,
- 9 A. H. Li¹, M. Zhang², J. Mbatchou¹, K. Watanabe¹, L. Gurski¹, S. E. McCarthy¹, H. M. Kang¹, L.
- 10 Dobbyn¹, E. Stahl¹, A. Verma⁴, G. Sirugo⁴, Regeneron Genetics Center*, M. D. Ritchie⁴, M.
- 11 Jones¹, S. Balasubramanian¹, K. Siminovitch¹, W. J. Salerno¹, A. R. Shuldiner¹, D. J. Rader⁴, T.
- Mirshahi³, A. E. Locke¹, J. Marchini¹, J. D. Overton¹, D. J. Carey³, L. Habegger¹, M. N. Cantor¹, 12
- 13 K. A. Rand², E. L. Hong², J. G. Reid¹, C. A. Ball², A. Baras^{1‡}, G. R. Abecasis^{1‡}, M. A. Ferreira^{1‡}
- 15 From:

21

26

- 16 ¹Regeneron Genetics Center, 777 Old Saw Mill River Rd., Tarrytown, NY 10591, USA
- 17 ²AncestryDNA, 1300 West Traverse Parkway, Lehi, UT 84043, USA
- 18 ³Geisinger, Danville, PA, 17822, USA
- 19 ⁴Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia,
- 20 PA, 19104, USA
- 22 *A complete list of investigators is provided in the Supplementary Appendix.
- 23 [†] J. E. Horowitz, J. A. Kosmicki and A. Damask contributed equally to this manuscript.
- 24 [‡]A. Baras, G. R. Abecasis and M. A. Ferreira jointly supervised this work.
- 25 Correspondence to: <u>manuel.ferreira@regeneron.com</u>
- 27 This research has been conducted using the UK Biobank Resource (Project 26041)

ABSTRACT

SARS-CoV-2 enters host cells by binding angiotensin-converting enzyme 2 (ACE2). Through a genome-wide association study, we show that a rare variant (MAF = 0.3%, odds ratio 0.60, $P=4.5\times10^{-13}$) that down-regulates ACE2 expression reduces risk of COVID-19 disease, providing human genetics support for the hypothesis that ACE2 levels influence COVID-19 risk. Further, we show that common genetic variants define a risk score that predicts severe disease among COVID-19 cases.

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

MAIN TEXT Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which has lead to >3 million deaths worldwide since December 2019 1. Reported risk factors for severe COVID-19, defined here as death or hospitalization combined with respiratory failure ², include male sex, older age, race, obesity, kidney, cardiovascular and respiratory diseases ³⁻⁵. In this study, we used human genetics to identify genetic variants associated with severe COVID-19 and tested the utility of genetic risk scores to identify individuals at highest risk of severe disease. We performed genome-wide association studies (GWAS) of COVID-19 outcomes across 52,630 individuals with COVID-19 and 704,016 individuals with no record of SARS-CoV-2 infection aggregated from four studies (Geisinger Health System [GHS], Penn Medicine BioBank [PMBB], UK Biobank [UKB] and AncestryDNA; Supplementary Table 1) and five continental ancestries. Of the COVID-19 cases, 6,911 (13.1%) were hospitalized and 2,184 (4.1%) had severe disease; hospitalized patients were more likely to be older, of non-European ancestry and to have preexisting cardiovascular and lung disease (Supplementary Table 2). Using these data, we defined two groups (risk and severity) of COVID-19 outcomes, ultimately resulting in five case-control comparisons related to risk of infection and two others related to disease severity among COVID-19 cases (Table 1 and Supplementary Table 3). For each comparison, we performed ancestryspecific GWAS in each study and then combined results using a fixed-effects meta-analysis. Genomic inflation factors (λ_{GC}) for the meta-analyses were <1.05, suggesting no substantial impact of population structure or unmodeled relatedness (Supplementary Table 4).

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

Our analysis provides independent support for several risk variants reported in previous GWAS of COVID-19 (Supplementary Table 5), including those recently reported by the COVID-19 Host Genetics Initiative (HGI) ⁶, to which we contributed an earlier version of these data (Supplementary Table 6). Details for these replicated loci follow below, but first we looked for novel genetic associations that might have been missed by the HGI. Across the seven risk and severity phenotypes, considering both common (MAF>0.5%, up to 13 million) and rare (MAF<0.5%, up to 76 million) variants, we observed one previously unreported association at a conservative $P < 8 \times 10^{-11}$ (Bonferroni correction for seven phenotypes x 89 million variants). This association was between lower risk of infection and rs190509934:C on the X-chromosome (MAF=0.3%, OR=0.60, 95% CI 0.52-0.69, $P = 4.5 \times 10^{-13}$; Figure 1A and 1B). This rare variant is located on the X chromosome, 60 base pairs upstream of the angiotensin-converting enzyme 2 gene (ACE2), the primary cell entry receptor for SARS-CoV-2 7. Given the potential significance of these findings, we studied the association between the ACE2 variant rs190509934 and COVID-19 outcomes in greater detail. We found that the variant was well imputed (imputation info score >0.6 for all studies), and that there was no evidence for differences in effect size (heterogeneity test P>0.05) across studies (Figure 1C) or ancestries (Supplementary Table 7). However, a significantly stronger association (P=0.009) was observed in males (OR=0.49, P=7.0x10⁻¹¹; explaining 0.085% of the variance in disease liability 8 , h^2) when compared to females (OR=0.72, $P=5\times10^{-4}$; $h^2=0.017\%$). There were no associations between rs190509934 and clinical risk factors for COVID-19 after correcting for multiple testing (Supplementary Table 8), suggesting that these were not likely confounders in the analysis. We then investigated the association between rs190509934 and severity among COVID-19 cases, and

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

found that carriers of rs190509934:C had numerically (but not significantly) lower risk of worse disease outcomes when compared to non-carriers (Supplementary Table 9). These results demonstrate that rs190509934 near ACE2 confers protection against SAR-CoV-2 infection and potentially also modulates disease severity among infected individuals; since the variant is rare, a definite account of its role on disease severity will require larger numbers of severe cases. We speculated that the protective rare variant near ACE2 (rs190509934:C) might regulate ACE2 expression. This variant was not characterized by GTEx 9 or other gene expression studies we queried (Supplementary Table 10). Thus, to test its association with ACE2 expression, we analyzed RNA-seq data from liver tissue available in a subset of 2,035 individuals from the GHS study, including eight heterozygous and one hemizygous carrier for rs190509934:C. After adjusting for potential confounders (e.g. body mass index, liver disease), we found that rs190509934:C reduced ACE2 expression by 0.87 standard deviation units (95% CI -1.18 to -0.57, $P=2.7\times10^{-8}$: Figure 1D). When considering raw, pre-normalized ACE2 expression levels. rs190509934:C was associated with a 39% reduction in expression relative to non-carriers. There was no association with the expression of 12 other nearby genes (within 500 kb) after accounting for multiple testing. These results are consistent with rs190509934:C lowering ACE2 expression, which in turn confers protection from SARS-CoV-2 infection. In addition to its role in viral infections, the normal physiologic role of ACE2 involves its hydrolysis and clearance of angiotensin II, a vasoconstrictive peptide that can lead to higher vascular tone or blood pressure ¹⁰. Therefore, we investigated if rs190509934:C was associated with higher systolic blood pressure in the UKB study, but found no significant association (beta=0.009 SD-units, P=0.56; Supplementary Table 11). There was a trend for higher blood

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

pressure among carriers of ultra-rare coding variants in ACE2 that are predicted to be full loss-offunction (beta=0.219, P=0.086; Supplementary Table 11), assayed through exome-sequencing as described previously 11. These results need to be confirmed in larger datasets, but suggest that ACE2 loss-of-function may modestly increase blood pressure. This should be considered if ACE2 blockade is to be developed for COVID-19 treatment, although pharmacologic inhibition of ACE2 in such a setting would be expected to be short term and elevations in blood pressure could be managed with anti-hypertensives. Of note, ACE2 expression in the airways was reported to be higher in smokers and patients with COPD ¹² and to increase with age ¹³. Collectively, these observations and our genetic findings are consistent with the hypothesis that ACE2 levels play a key role in determining COVID-19 risk. As noted, our GWAS also identified associations at several loci reported in previous GWAS of COVID-19 outcomes. To explore previously reported signals in detail, we first attempted to replicate eight independent associations ($r^2 < 0.05$) with disease risk (Supplementary Table 5) reported in three recent GWAS that included >1,000 cases (Supplementary Table 6). After accounting for multiple testing, six variants had a significant (P<0.0012) and directionally consistent association in at least one of our five disease risk analyses (Supplementary Table 12), specifically those located in/near LZTFL1, SLC6A20, MHC, ABO, DPP9 and IFNAR2. There was no evidence for heterogeneity in effect sizes across studies (Supplementary Table 12) or ancestries (Supplementary Table 13). We also explored the possibility that the association between these six variants and COVID-19 risk could have been confounded by disease status for relevant comorbidities. We found that only two of the six variants were modestly associated with a clinical risk factor (Supplementary Table 8), and we conclude that it is unlikely that the

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

association between the six variants and risk of COVID-19 is explained by these underlying comorbidities. To evaluate whether genetics could be used to predict severe disease, we first investigated which replicated variants were associated with severity amongst COVID-19 cases. Among the six replicated variants (in/near LZTFL1, SLC6A20, MHC, ABO, DPP9 and IFNAR2), four were significantly (P<0.05) associated with worse outcomes among infected individuals (in/near LZTFL1, MHC, DPP9 and IFNAR2), while those in ABO and near SLC6A20 did not associate with COVID-19 severity (Supplementary Figure 1B and Supplementary Table 14). Collectively, these results highlight four variants associated with both COVID-19 risk and worse disease outcomes, including respiratory failure and death. These variants may be used to identify individuals at risk of severe COVID-19 and to guide the search for genes involved in the pathophysiology of COVID-19. We next evaluated whether variants identified by the COVID-19 HGI, a large worldwide effort to identify genetic risk factors for COVID-19, could augment this set of four disease severity variants. The latest HGI analyses⁶ include data from 49,562 SARS-CoV-2 infected individuals and use >1.7 million individuals with no record of infection as controls (Supplementary Table 15). To identify additional variants associated with severity, we started with variants associated with the phenotype "reported infection" (infected vs. no record of infection) which, despite the sample overlap between the HGI and our analyses, is statistically independent from severity among infected individuals – since infection status (positive vs. negative or unknown) is uncorrelated with hospitalization status once infected (hospitalized vs. not hospitalized). We found that two were nominally associated with risks of hospitalization or severe disease among cases (rs11919389 near

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

RPL24 and rs1886814 near FOXP4; Supplementary Table 15), suggesting that these loci also modulate disease severity after infection with SARS-CoV-2. Collectively, our association analyses highlighted six common variants identified in previous GWAS or by the HGI - in/near LZTFL1, MHC, DPP9, IFNAR2, RPL24 and FOXP4 - that are associated with risk of COVID-19 as well as disease severity among cases. To help identify genes that might underlie the observed associations, we searched for functional protein-coding variants (missense or predicted loss-of-function) in high LD ($r^2 > 0.80$) with each variant. We found eight functional variants in five genes (Supplementary Table 16): IFNAR2, a cytokine receptor component in the anti-viral type 1 interferon pathway, which is activated by SARS-CoV-2 and is dysregulated in severe COVID-19 cases 14-16; CCHCR1, a P-body protein associated with cytoskeletal remodeling and mRNA turnover ^{17,18}; TCF19, a transcription factor associated with hepatitis B ¹⁹; and *C6orf15* and *PSORS1C1*, two functionally uncharacterized genes in the MHC. These data indicate that the risk variants identified may have functional effects on these five genes. Next, we asked if any of the six sentinel risk variants co-localized (i.e. were in high LD, $r^2 > 0.80$) with published sentinel expression quantitative trait loci (eQTL) across 52 studies (Supplementary Table 10), specifically focusing on 114 genes in cis (\pm 500 kb). We found colocalization with sentinel eQTL for eight genes (Supplementary Table 17): SLC6A20 (eQTL from lung), a proline transporter that binds the host SARS-CoV-2 receptor, ACE2 ²⁰; NXPE3 (esophagus), a gene of uknown function; SENP7 (blood), a SUMO-specific protease that promotes interferon signaling and that in mice is essential for innate defense against herpes simplex virus 1 infection²¹; IFNAR2 and TCF19 (multiple tissues), both discussed above; LST1 (blood), an

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

immune modulatory protein that inhibits lymphocyte proliferation ²² and is upregulated in response to bacterial ligands ²³; *HLA-C* (adipose), a natural killer cell ligand, associated with viral infection ²⁴ and autoimmunity ²⁵; and *IL10RB* (multiple tissues), a pleotropic cytokine receptor associated with persistent hepatitis B and autoimmunity 26,27 . Collectively, analysis of missense variation and eQTL catalogs suggests 12 potential effector genes in COVID-19 loci (ACE2, C6orf15, CCHCR1, HLA-C, IFNAR2, IL10RB, LST1, NXPE3, PSORS1C1, SENP7, SLC6A20 and TCL19), though functional studies are required to confirm these predictions. Next, we proceeded to evaluate if common genetic variants can help identify individuals at high risk of severe disease. Specifically, we focused on the six variants (in/near LZTFL1, MHC, DPP9, IFNAR2, RPL24 and FOXP4) that associated with both risk of COVID-19 and disease severity among infected individuals. Using these variants, we created a weighted genetic risk score (GRS) for individuals with COVID-19 and then compared the risk of hospitalization and severe disease between those with a high GRS and all other cases, after adjusting for established risk factors. The weights used for each variant corresponded to the effect size (log of the odds ratio) reported in previous GWAS. When considering COVID-19 cases of European ancestry (N=44,958), we found that having a high GRS (top 10%) was associated with a 1.38-fold increased risk of hospitalization $(95\% \text{ CI } 1.26 \text{ to } 1.53, P=6x10^{-11};$ **Figure 2A**) and 1.58-fold increased risk of severe disease $(95\% \text{ CI } 1.26 \text{ to } 1.53, P=6x10^{-11};$ CI 1.36 to 1.82, $P=7\times10^{-10}$; Figure 2B). In other ancestries, a high GRS also appeared to predict risk of hospitalization – including among individuals of African ancestry (N=2,598, 1.70-fold risk for high GRS, 95% CI 1.03 to 2.81, P=0.038), Admixed American ancestry (N=3,752, 1.56-fold risk, 95% CI 1.00 to 2.43, P = 0.05) and South Asian ancestry (N=760, 1.42-fold risk, 95% CI

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

0.72 to 2.82, P = 0.32, Supplementary Table 18). A similar pattern was observed for risk of severe disease, though sample sizes were considerably smaller (Supplementary Tables 19). We then compared the effect of the GRS between individuals with and without established risk factors for severe COVID-19. In Europeans of both the AncestryDNA and UK Biobank studies, we found that a high GRS (top 10%) was associated with risk of severe disease both among individuals with and without established clinical risk factors for severe COVID-19 (Figure 3). In the meta-analysis of the two studies, a high GRS was associated with a 1.65-fold (95% CI 1.39-1.96, $P=1\times10^{-8}$) and 1.75-fold (95% CI 1.28-2.40, $P=4\times10^{-4}$) higher risk of severe disease, respectively among individuals with and without established risk factors (Supplementary Table 20). There was no evidence for heterogeneity of GRS effect with clinical risk factor status (P=0.30). Similar results were observed for (i) risk of hospitalization (Supplementary Figure 2 and Supplementary Table 20); (ii) when including in the GRS all 12 variants reported to associate with risk of COVID-19 in previous GWAS (eight variants) and by the HGI (four novel variants associated with reported infection; Supplementary Figure 3); and (iii) in individuals of Admixed American ancestry (Supplementary Figure 4; stratitifed analysis not performed in other ancestries due to small sample size). Lastly, we also found that expanding the GRS to include a larger set of variants did not improve the observed associations (Supplementary Figure 5). Overall, these results demonstrate that a GRS calculated using variants associated with disease risk and severity can potentially be used to identify COVID-19 cases at high risk of developing poor disease outcomes. We note that preeminent factor for severe COVID-19 outcomes remains age (as illustrated in Supplementary Figure 6), but that common genetic variants appear to provide complementary information that may be used to stratify risk among older individuals.

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

The following caveats should be considered when interpreting results from this study. First, our study had greater power to identify associations with disease risk than with severity outcomes, given the relatively small sample size for the latter. Second, there was phenotypic heterogeneity among COVID-19 cases and controls and associated risk factors across our studies. One likely reason for this is that survey respondents from the AncestryDNA study were enriched for healthier individuals and milder COVID-19 cases, when compared to participants of the UKB, GHS and PMBB studies, who were ascertained in clinical settings and so were enriched for hospitalized and severe COVID-19 cases. Other sources of heterogeneity may include regional and temporal availability of COVID-19 testing and the inability to control for viral exposure among controls. While our meta-analysis collectively spans a broad phenotypic spectrum, these individual differences may account for variability in results across reported studies. Third, we used expression levels measured in liver to assess the impact of the ACE2 risk variant on gene expression. Liver is not the most relevant tissue to assess ACE2 expression, but we note that cis eQTLs are often shared across tissues ^{9,28}. Fourth, the association between GRS and risk of severe disease was strongest in European individuals of the AncestryDNA (OR=1.72, $P=2x10^{-6}$) and UKB (OR=1.65, $P=6x10^{-6}$) studies when compared to the smaller GHS study (OR=1.03, P=0.877). The lower effect size in the latter may be due to differences in ascertainment of COVID-19 positive cases, as discussed above, or stochastic, given the smaller sample size. We also noted that the impact of the GRS on risk of hospitalization was attenuated in comparison to severe disease, which may be a reflection of the weighting schema for the variants comprising the score; the four largest GRS weights were derived from an analysis of critically ill individuals.

In summary, we confirmed six common variant associations with risk of infection and further show that four of these variants modulate disease severity among cases. We also identified one novel association with disease risk which provides human genetic support for the hypothesis that ACE2 expression plays a key role SARS-CoV-2 infection and may constitute an attractive therapeutic target for prevention COVID-19 disease and its sequelae. Lastly, we demonstrate that a genetic risk score based on common variants validated in this study can be used to identify individuals at high risk of poor disease outcomes.

ONLINE METHODS

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

Participating Studies AncestryDNA COVID-19 Research Study. AncestryDNA customers over age 18, living in the United States, and who had consented to research, were invited to complete a survey assessing COVID-19 outcomes and other demographic information. These included SARS-CoV-2 swab and antibody test results, COVID-19 symptoms and severity, brief medical history, household and occupational exposure to SARS-CoV-2, and blood type. A total of 163,650 AncestryDNA survey respondents were selected for inclusion in this study ²⁹. Respondents selected for this study included all individuals with a positive COVID-19 test together with age and sex matched controls. DNA samples were genotyped as described previously²⁹. Genotype data for variants not included in the array were then inferred using imputation to the Haplotype Reference Consortium (HRC) reference panel. Briefly, samples were imputed to HRC version 1.1, which consists of 27,165 total individuals and 36 million variants. The HRC reference panel does not include indels; consequently, indels are not present in the imputed data. We determined best-guess haplotypes with Eagle version 2.4.1 and performed imputation with Minimac4 version 1.0.1. We used 1,117,080 unique variants as input and 8,049,082 imputed variants were retained in the final data set. Variants with a Minimac4 R²<0.30 were filtered from the analysis. Geisinger Health System (GHS). The GHS MyCode Community Health Initiative is a health system-based cohort from central and eastern Pennsylvania (USA) with ongoing recruitment since 2006³⁰. A subset of 144,182 MyCode participants sequenced as part of the GHS-Regeneron Genetics Center DiscovEHR partnership were included in this study. Information on COVID-19 outcomes were obtained through GHS's COVID-19 registry. Patients were identified as eligible

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

for the registry based on relevant lab results and ICD-10 diagnosis codes; patient charts were then reviewed to confirm COVID-19 diagnoses. The registry contains data on outcomes, comorbidities, medications, supplemental oxygen use, and ICU admissions. DNA from participants was genotyped on either the Illumina OmniExpress Exome (OMNI) or Global Screening Array (GSA) and imputed to the TOPMed reference panel (stratified by array) using the TOPMed Imputation Server. Prior to imputation, we retained variants that had a MAF \geq 0.1%, missingness \leq 1% and HWE p-value $> 10^{-15}$. Following imputation, data from the OMNI and GSA datasets were merged for subsequent association analyses, which included an OMNI/GSA batch covariate, in addition to other covariates described below. Penn Medicine BioBank (PMBB) study. PMBB contains ~70,000 study participants, all recruited through the University of Pennsylvania Health System (UPHS). Participants donate blood or tissue and allow access to EHR information ³¹. The PMBB participants with COVID-19 infection were identified through the UPHS COVID-19 registry, which consists of qPCR results of all patients tested for SARS-CoV-2 infection within the health system. We then used electronic health records to classify COVID-19 patients into hospitalized and severe (ventilation or death) categories. DNA genotyping was performed with the Illumina Global Screening Array, and imputation performed using the TOPMed reference panel as described for GHS above. UK Biobank (UKB) study. We studied the host genetics of SARS-CoV-2 infection in participants of the UK Biobank study, which took place between 2006 and 2010 and includes approximately 500,000 adults aged 40-69 at recruitment. In collaboration with UK health authorities, the UK Biobank has made available regular updates on COVID-19 status for all participants, including results from four main data types: qPCR test for SARS-CoV-2, anonymized electronic health records, primary care and death registry data. We report results based on phenotype data downloaded on the 4th January 2021 and excluded from the analysis 28,547 individuals with a death registry event prior to 2020. DNA samples were genotyped as described previously ³² using the Applied Biosystems UK BiLEVE Axiom Array (N=49,950) or the closely related Applied Biosystems UK Biobank Axiom Array (N=438,427). Genotype data for variants not included in the arrays were inferred using the TOPMed reference panel, as described above.

COVID-19 phenotypes used for genetic association analyses

We grouped participants from each study into three broad COVID-19 disease categories (Supplementary Table 1): (i) positive – those with a positive qPCR or serology test for SARS-CoV-2, or with a COVID-19-related ICD10 code (U07), hospitalization or death; (ii) negative – those with only negative qPCR or serology test results for SARS-CoV-2 and with no COVID-19-related ICD10 code (U07), hospitalization or death; and (iii) unknown – those with no qPCR or serology test results and no COVID-19-related ICD10 code (U07), hospitalization or death. We then used these broad COVID-19 disease categories, in addition to hospitalization and disease severity information, to create seven COVID-19-related phenotypes for genetic association analyses, as detailed in Supplementary Table 3.

SARS-CoV-2 infection status (positive, negative or unknown) was determined based on a qPCR test for SARS-CoV-2 in the UKB, GHS and PMBB studies; self-reported results for qPCR or serology test for SARS-CoV-2 in the AncestryDNA study.

Hospitalization status (positive, negative or unknown) was determined based on COVID-19-related ICD10 codes U071, U072, U073 in variable 'diag_icd10' (table 'hesin_diag') in the

UKB study; self-reported hospitalization due to COVID-19 in the AncestryDNA study; medical records in the GHS and PMBB studies.

Disease severity status (severe [ventilation or death] or not severe) was determined in the UKB study based on (i) respiratory support ICD10 code Z998 in variable 'diag_icd10' (table 'hesin_diag'); (ii) the following respiratory support ICD10 codes in variable 'oper4' (table 'hesin_oper'): E85, E851, E852, E853, E854,E855, E856, E858, E859, E87, E871, E872, E873, E874, E878, E879, E89, X56, X561, X562, X563, X568, X569, X58, X581, X588, X589; or (3) COVID-19-related ICD10 codes U071, U072, U073 in cause of death (variable 'cause_icd10' in table 'death_cause'). In the AncestryDNA study, disease severity was determined based on self-reported ventilation or need for supplementary oxygen due to COVID-19. In the GHS and PMBB study, it was determined based on ventilator or high-flow oxygen use.

For association analysis in the AncestryDNA study, we excluded from the COVID-19 unknown group individuals who had (i) a first-degree relative who was COVID-19 positive; or (ii) flu-like symptoms.

Genetic association analyses

Association analyses in each study were performed using the genome-wide Firth logistic regression test implemented in REGENIE 33 . In this implementation, Firth's approach is applied when the p-value from standard logistic regression score test is below 0.05. We included in step 1 of REGENIE (*i.e.* prediction of individual trait values based on the genetic data) directly genotyped variants with a minor allele frequency (MAF) >1%, <10% missingness, Hardy-Weinberg equilibrium test *P*-value>10⁻¹⁵ and linkage-disequilibrium (LD) pruning (1000 variant windows, 100 variant sliding windows and r^2 <0.9). The association model used in step 2 of

REGENIE included as covariates age, age², sex, age-by-sex, and the first 10 ancestry-informative principal components (PCs) derived from the analysis of a stricter set of LD-pruned (50 variant windows, 5 variant sliding windows and r^2 <0.5) common variants from the array (imputed for the GHS study) data.

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

Within each study, association analyses were performed separately for five different continental ancestries defined based on the array data: African (AFR), Admixed American (AMR), European (EUR) and South Asian (SAS). We determined continental ancestries by projecting each sample onto reference principle components calculated from the HapMap3 reference panel. Briefly, we merged our samples with HapMap3 samples and kept only SNPs in common between the two datasets. We further excluded SNPs with MAF<10%, genotype missingness >5% or Hardy-Weinberg Equilibrium test p-value < 10⁻⁵. We calculated PCs for the HapMap3 samples and projected each of our samples onto those PCs. To assign a continental ancestry group to each non-HapMap3 sample, we trained a kernel density estimator (KDE) using the HapMap3 PCs and used the KDEs to calculate the likelihood of a given sample belonging to each of the five continental ancestry groups. When the likelihood for a given ancestry group was >0.3, the sample was assigned to that ancestry group. When two ancestry groups had a likelihood >0.3, we arbitrarily assigned AFR over EUR, AMR over EUR, AMR over EAS, SAS over EUR, and AMR over AFR. Samples were excluded from analysis if no ancestry likelihoods were >0.3, or if more than three ancestry likelihoods were > 0.3.

Results were subsequently meta-analyzed across studies and ancestries using an inverse variance-weighed fixed-effects meta-analysis.

Identification of putative targets of GWAS variants based on colocalization with eQTL

We identified as a likely target of a sentinel GWAS variant any gene for which a sentinel expression quantitative trait locus (eQTL) co-localized (*i.e.* had LD $r^2 > 0.80$) with the sentinel GWAS variant. That is, we only considered genes for which there was strong LD between a sentinel GWAS variant and a sentinel eQTL, which reduces the chance of spurious colocalization. Sentinel eQTL were defined across 174 published datasets (**Supplementary Table 10**), as described previously ³⁴. We did not use statistical approaches developed to distinguish colocalization from shared genetic effects because these have very limited resolution at high LD levels ($r^2 > 0.80$) ³⁵.

Gene expression analysis in participants of the GHS study

For a subset of individuals from the GHS study (n=2,035, ascertained through the Geisinger Bariatric Surgery Clinic), RNA was extracted from liver biopsies conducted during bariatric surgery to evaluate liver disease. Individuals had class 3 obesity (BMI>40kg/m²) or class 2 obesity (BMI 35-39 kg/m²) with an obesity-related co-morbidity (e.g. type-2 diabetes, hypertension, sleep apnea, non-alcoholic fatty liver disease). RNA libraries were prepared using polyA-extraction and then sequenced with 75bp paired-end reads with two 10 bp index reads on the Illumina NovaSeq 6000 on S4 flow cells. RNA-seq data were then analyzed using the GTEx v8 workflow³6, using STAR ³7 and RNASeqQC ³8, except that GENCODE v32 was used in lieu of v26. Briefly: (i) raw expression counts were normalized with TMM (Trimmed Mean of M-values) as implemented in edgeR ³8; (ii) a rank-based inverse normal transformation was applied to the normalized expression values; (iii) principal components (PCs) analysis was performed on data from 25,078 genes with TPM >0.1 in >20% samples, to identify latent factors accounting for variation in gene expression; (iv) gene expression levels were adjusted for the top 100 PCs to improve power to identify cis-

regulatory effects. The association between adjusted *ACE2* expression and the imputed genotypes of rs190509934 was then tested using REGENIE, with the following variables included as covariates: age, age², four ancestry-informative principal components, steatosis status, fibrosis status, diabetes status, and body mass index at the time of bariatric surgery.

Genetic risk score (GRS) analysis of COVID-19 hospitalization and severity

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

First, in each study (AncestryDNA, GHS, UKB and PMBB), we created a GRS for each COVID-19 positive individual based on variants that were reported to associate with risk of COVID-19 in previous GWAS and that we (i) independently replicated (except variants identified by the HGI); and (ii) found to be associated with COVID-19 severity outcomes. We used as weights the effect (beta) reported in previous GWAS (Supplementary Table 5). Second, we ranked COVID-19 individuals based on the GRS and created a new binary GRS predictor by assigning each individual to a high (top 5%) or low (rest of the population) percentile group. Third, for studies with >100 hospitalized cases, we used logistic regression to test the association between the binary GRS predictor and risk of hospitalization (hospitalized cases vs. all other cases), including as covariates age, sex, age-by-sex interaction, and ten ancestry-informative PCs. In addition to age and sex, we included as additional covariates established clinical risk factors for COVID-19 that are outlined in the Emergency Use Authorisation treatment guidelines for casirivimab and imdevimb: BMI, chronic kidney disease, diabetes, immunosuppressive disease, chronic obstructive pulmonary disease or other chronic respiratory disease, cardiovascular disease and hypertension. We repeated the association analysis (i) using different percentile cut-offs for the GRS (5%, 10%, 20%, 30% and 40%); and (ii) to test the association with disease severity (severe cases vs. all other cases). We then stratified COVID-19 cases by clinical risk (high versus lower) and evaluated the

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

association between the top 10% by GRS (i.e. high genetic risk) and risk of hospitalization or severe disease. The stratified analyses were performed with logistic regression, with sex and ancestry-informative PCs included as covariates. High clinical risk was defined as any one of the following: (i) age ≥65; (ii) BMI ≥35; (iii) chronic kidney disease, diabetes or immunosuppressive disease; (iv) age ≥55 and presence of chronic obstructive pulmonary disease/other chronic respiratory disease, cardiovascular disease, or hypertension. **Code availability** Upload Agent (v1.5.30) can be found at https://wiki.dnanexus.com/Downloads#Upload-Agent. bcl2fastq software (v2.19.0) can be found at https://support.illumina.com/sequencing/sequencing_software/bcl2fastq-conversionsoftware.html. BWA software (v0.7.17) for read alignment can be found at http://biobwa.sourceforge.net. Picard software (v1.141) can be found at https://broadinstitute.github.io/picard/. Samtools (v1.7) can be found at http://www.htslib.org. WeCall (v1.1.2) can be found at https://github.com/Genomicsplc/wecall. FastQC (v0.11.8) can be found at http://www.bioinformatics/babraham.ac.uk/projects/fastqc/. Beftools, bgzip, and tabix (v1.7) can be found at http://www.htslib.org, bgzip/tabix v1.7. pigz (v2.3.4) can be found at https://zlib.net/pigz/. Eagle (v2.4.1) can be found at https://github.com/poruloh/Eagle. Minimac4 (v1.01) can be found at https://github.com/statgen/Minimac4. GLnexus (v0.4.0) can be found at https://github.com/dnanexus-rnd/GLnexus. PLINK (v1.90b6.21) can be found at https://www.cog-genomics.org/plink2/. PRIMUS can be found at https://primus.gs.washington.edu/primusweb/. REGENIE (v2.0.1) can be found at https://github.com/statgen/METAL.

Data availability

All genotype-phenotype association results reported in this study are available for browsing using the RGC's COVID-19 Results Browser (https://rgc-covid19.regeneron.com). Data access and use is limited to research purposes in accordance with the Terms of Use (https://rgc-covid19.regeneron.com/terms-of-use).

438

439

440

441

442

443

444

445

446

447

448

449


450


451

452

Competing interests J.E.H., J.A.K., A.D., D.S., N.B, A.Y., A.M., R.L., E.M., X.B., D.S., F.S.P.K., J.D.B., C.O'D., A.J.M., D.A.T., A.H.L., J.M., K.W., L.G., S.E.M, H.M.K., L.D., E.S., M.J., S.B., K.S.M, W.J.S., A.R.S., A.E.L., J.M., J.O., L.H., M.N.C., J.G.R., A.B., G.R.A., and M.A.F. are current employees and/or stockholders of Regeneron Genetics Center or Regeneron Pharmaceuticals. G.H.L.R., M.V.C., D.S.P., S.C.K. A.Bal., A.R.G., S.R.M., R.P., M.Z., K.A.R., E.L.H., C.A.B. are current employees at AncestryDNA and may hold equity in AncestryDNA. The other authors declare no competing interests. Acknowledgements This research has been conducted using the UK Biobank Resource (Project 26041). The Penn Medicine BioBank is funded by a gift from the Smilow family, the National Center for Advancing Translational Sciences of the National Institutes of Health under CTSA Award Number UL1TR001878, and the Perelman School of Medicine at the University of Pennsylvania. We want to acknowledge the participants and investigators of the FinnGen study. We thank the AncestryDNA customers who voluntarily contributed information in the COVID-19 survey.

FIGURES








Figure 1. GWAS of 52,630 COVID-19 positive cases vs. 704,016 COVID-19 negative or unknown controls identifies a novel association with a rare variant near *ACE2* that lowers gene expression and protects against COVID-19.

(A) Summary of association results for common (MAF>0.5%) and rare (MAF<0.5%) variants.

(B) Regional association plot centered around rs190509934 near ACE2.

(C) Breakdown of association results across studies included in the meta-analysis of rs190509934.

(D) Association between rs190509934:C and *ACE2* expression in liver measured in 2,035 individuals from the GHS study.

A. Risk of hospitalization

467

468 469

470

471

472

473

474

475

476

477

478

479

480

481

Meta-analysis of UK Biobank, AncestryDNA and GHS 2.00 P<5x10-8 Odds Ratio if GRS in top percentile P<5x10⁻⁴ 1.75 1.25 1.25 17296 13366 8916 4419 2212 27662 31592 36042 40539

Top 20%

Percentile of genetic risk score (GRS)


Top 10%

Top 5%

Top 40%

Top 30%

B. Risk of severe disease



Percentile of genetic risk score (GRS)


Figure 2. Association between a 6-SNP genetic risk score (GRS) and risk of hospitalization (A) and severe disease (B) among COVID-19 cases of European ancestry.

(A) Association between high genetic risk and hospitalization. Risk of hospitalization among cases is shown for individuals in the top GRS percentile, agnostic to the number of clinical risk factors present. The association was tested in three studies separately (AncestryDNA, UKB and GHS studies) using logistic regression, with established risk factors for COVID-19 included as covariates (see Methods for details). Results were then meta-analyzed across studies, for a combined sample size of 44,958 COVID-19 cases, including 6,138 hospitalized. N in red: number of COVID-19 cases in the top GRS percentile. Error bars represent 95% confidence intervals.

(B) Association between high genetic risk and severe disease. The association was tested as described above in three studies separately (AncestryDNA, UKB and GHS studies). Results were then meta-analyzed across studies, for a combined sample size of 44,958 COVID-19 cases, including 1,940 with severe disease.

- N in red: number of COVID-19 cases in the top GRS percentile. N in grey: number of COVID-19
- 483 cases in the rest of population.

A. Ancestry DNA study



B. UK Biobank study

485

486

487

488

489

490

491

492

493




Figure 3. Association between a 6-SNP genetic risk score (GRS) and risk of severe disease among COVID-19 cases of European ancestry after stratifying by the presence of clinical risk factors.

- (A) Rate of severe disease in the AncestryDNA study (25,353 COVID-19 cases, including 667 with severe disease).
- (B) Rate of severe disease in the UK Biobank study (14,320 COVID-19 cases, including 951 with severe disease).
- High genetic risk (red bars): top 10% of the GRS. Low genetic risk (grey bars): bottom 90% of the GRS (*i.e.* all other COVID-19 cases). Error bars (black) represent 95% confidence intervals.

TABLES

Table 1. Seven COVID-19 phenotypes analyzed in this study.

Broad phenotype category	Phenotype	Description	Group	Sample size with genetic data
Risk of infection	COVID-19 positive	Risk of infection	Cases	52,630
	vs. COVID-19 negative or unknown		Controls	704,016
	COVID-19 positive	Risk of infection among individuals tested for SARS-CoV-2	Cases	52,630
	vs. COVID-19 negative		Controls	109,605
	COVID-19 positive and not hospitalized	Risk of infection that does not require hospitalization	Cases	45,641
	vs. COVID-19 negative or unknown		Controls	704,016
	COVID-19 positive and hospitalized	Risk of infection that requires hospitalization	Cases	6,911
	vs. COVID-19 negative or unknown		Controls	689,620
	COVID-19 positive and severe	Risk of infection with severe outcomes	Cases	2,184
	vs. COVID-19 negative or unknown		Controls	689,620
Risk of severe outcomes among infected individuals	COVID-19 positive and hospitalized	Risk of hospitalization among infected individuals	Cases	6,911
	vs. COVID-19 positive and not hospitalized		Controls	45,185
	COVID-19 positive and severe	Risk of severe disease among infected individuals	Cases	2,184
	vs. COVID-19 positive and not hospitalized		Controls	45,185

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

SUPPLEMENTARY FIGURES Provided in a separate file. Supplementary Figure 1. Comparison of effect sizes across COVID-19 risk and severity outcomes for six previously reported novel risk variants that validated in this study. Six variants were reported to associate with risk of COVID-19 in previous studies and replicated in our analysis. Of these, four variants also associated with disease severity among COVID-19 cases (in/near LZTFL1, CCHCR1, DPP9 and IFNAR2), whereas two variants did not (in ABO and *SLC6A20*). Error bars represent 95% confidence intervals. Supplementary Figure 2. Association between a 6-SNP genetic risk score (GRS) and risk of hospitalization among COVID-19 cases of European ancestry after stratifying by the presence of clinical risk factors. (A) Rate of hospitalization in the AncestryDNA study (25,353 COVID-19 cases, including 1,484 hospitalized). (B) Rate of hospitalization in the UK Biobank study (14,320 COVID-19 cases, including 3,878 hospitalized). High genetic risk (red bars): top 10% of the GRS. Low genetic risk (grey bars): bottom 90% of the GRS (i.e. all other COVID-19 cases). Supplementary Figure 3. Association between a 6- and 12-SNP genetic risk score (GRS) and risk of hospitalization and severe disease among COVID-19 cases of European ancestry. To evaluate if the association between the GRS and worse disease outcomes was dependent on the

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

list of variants selected for analysis, we compared results between GRS calculated using different sets of variants. We considered a GRS calculated using: (i) the six variants that were reported in previous GWAS of COVID-19 and that we validated the published association and further showed that they were associated with risk of hospitalization or severe disease among COVID-19 cases (in/near LZTFL1, MHC, DPP9, IFNAR2, RPL24 and FOXP4; see Supplementary Figure 1); or (ii) all 12 variants reported in previous GWAS of COVID-19 (in/near LZTFL1 [two variants], MHC, ABO, OAS3, DPP9, RAVER1, IFNAR2; and four novel risk variants discovered by the HGI in/near RPL24, DNAH5, FOXP4 and PLEKHA4; see Supplementary Tables 5 and 15). Analyses were performed separately in the UK Biobank, AncestryDNA and GHS studies (risk of hospitalization only) after stratifying COVID-19 cases by the presence of clinical risk factors, considering individuals with lower clinical risk (blue circles), high clinical risk (green triangles) or all individuals (grey squares). Association results were then meta-analyzed across studies. Supplementary Figure 4. Association between a six-SNP genetic risk score (GRS) and risk of hospitalization (A) and (B) severe disease among COVID-19 cases of Admixed American ancestry. Supplementary Figure 5. Association between risk of severe disease among COVID-19 cases of European ancestry and genetic risk scores determined based on different criteria. We compared GRS based on variants (i) that were reported in the literature and validated in this study (Literature.HGI.1var: rs73064425 in LZTFL1; Literature.HGI.5var: variants from our 6-SNP model, with the exception of rs73064425 in LZTFL1; Literature.HGI.6var: all six variants from our 6-SNP model); (ii) obtained through pruning and thresholding applied to results from the risk

of infection phenotype reported by the HGI, using different association P-value and LD r^2 thresholds; (iii) the LDpred approach ³⁹ applied to risk of infection reported by the HGI, considering different ϱ parameters.

Supplementary Figure 6. Association between risk of severe disease among COVID-19 cases of European ancestry from the UK Biobank study and combination of clinical risk factors, genetic risk (6-SNP GRS model) and age.

SUPPLEMENTARY TABLES

Provided in a separate file.

552


References

- 556 1. Zhu, N. *et al.* A Novel Coronavirus from Patients with Pneumonia in China, 2019. *New England Journal of Medicine* **382**, 727-733 (2020).
- 558 2. Guan, W.J. *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* **382**, 1708-1720 (2020).
- Zhou, F. *et al.* Clinical course and risk factors for mortality of adult inpatients with
 COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 395, 1054-1062 (2020).
- 562 4. Cummings, M.J. *et al.* Epidemiology, clinical course, and outcomes of critically ill adults 563 with COVID-19 in New York City: a prospective cohort study. *Lancet* **395**, 1763-1770 564 (2020).
- 565 5. Lopez, L., 3rd, Hart, L.H., 3rd & Katz, M.H. Racial and Ethnic Health Disparities Related to COVID-19. *JAMA* (2021).
- 567 6. The COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19 by worldwide meta-analysis. in *medRxiv* (2021).
- 7. Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270-273 (2020).
- 571 8. Pawitan, Y., Seng, K.C. & Magnusson, P.K. How many genetic variants remain to be discovered? *PLoS One* **4**, e7969 (2009).
- 573 9. Consortium, G.T. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science* **369**, 1318-1330 (2020).
- 575 10. Keidar, S., Kaplan, M. & Gamliel-Lazarovich, A. ACE2 of the heart: From angiotensin I to angiotensin (1-7). *Cardiovasc Res* **73**, 463-9 (2007).
- 577 11. Van Hout, C.V. *et al.* Exome sequencing and characterization of 49,960 individuals in the UK Biobank. *Nature* (2020).
- 579 12. Saheb Sharif-Askari, N. *et al.* Airways Expression of SARS-CoV-2 Receptor, ACE2, and TMPRSS2 Is Lower in Children Than Adults and Increases with Smoking and COPD. *Mol Ther Methods Clin Dev* **18**, 1-6 (2020).
- 582 13. Bunyavanich, S., Do, A. & Vicencio, A. Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults. *JAMA* **323**, 2427-2429 (2020).
- Hadjadj, J. *et al.* Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. *Science* **369**, 718-724 (2020).
- 586 15. van der Made, C.I. *et al.* Presence of Genetic Variants Among Young Men With Severe COVID-19. *JAMA* (2020).
- 588 16. Zhang, Q. *et al.* Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science* **370**(2020).
- 590 17. Ling, Y.H. *et al.* CCHCR1 interacts with EDC4, suggesting its localization in P-bodies. *Exp* 591 *Cell Res* **327**, 12-23 (2014).
- 592 18. Tervaniemi, M.H. *et al.* Intracellular signalling pathways and cytoskeletal functions 593 converge on the psoriasis candidate gene CCHCR1 expressed at P-bodies and 594 centrosomes. *BMC Genomics* **19**, 432 (2018).
- 595 19. Kim, Y.J. *et al.* A genome-wide association study identified new variants associated with the risk of chronic hepatitis B. *Hum Mol Genet* **22**, 4233-8 (2013).


- 597 20. Vuille-dit-Bille, R.N. *et al.* Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors. *Amino Acids* **47**, 693-705 (2015).
- 599 21. Cui, Y. *et al.* SENP7 Potentiates cGAS Activation by Relieving SUMO-Mediated Inhibition of Cytosolic DNA Sensing. *PLoS Pathog* **13**, e1006156 (2017).
- Rollinger-Holzinger, I. *et al.* LST1: a gene with extensive alternative splicing and immunomodulatory function. *J Immunol* **164**, 3169-76 (2000).
- 603 23. Mulcahy, H., O'Rourke, K.P., Adams, C., Molloy, M.G. & O'Gara, F. LST1 and NCR3 expression in autoimmune inflammation and in response to IFN-gamma, LPS and microbial infection. *Immunogenetics* **57**, 893-903 (2006).
- 606 24. Apps, R. *et al.* Influence of HLA-C expression level on HIV control. *Science* **340**, 87-91 (2013).
- 608 25. Kulkarni, S. *et al.* Genetic interplay between HLA-C and MIR148A in HIV control and Crohn disease. *Proc Natl Acad Sci U S A* **110**, 20705-10 (2013).
- Begue, B. *et al.* Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. *Am J Gastroenterol* **106**, 1544-55 (2011).
- Frodsham, A.J. *et al.* Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. *Proc Natl Acad Sci U S A* **103**, 9148-53 (2006).
- 614 28. Qi, T. *et al.* Identifying gene targets for brain-related traits using transcriptomic and methylomic data from blood. *Nat Commun* **9**, 2282 (2018).
- 616 29. Roberts, G.H.L. AncestryDNA COVID-19 Host Genetic Study Identifies Three Novel Loci. 617 medRxiv (2020).
- Dewey, F.E. *et al.* Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study. *Science* **354**(2016).
- Park, J. *et al.* A genome-first approach to aggregating rare genetic variants in LMNA for association with electronic health record phenotypes. *Genet Med* **22**, 102-111 (2020).
- Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.

 Nature **562**, 203-209 (2018).
- 624 33. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and binary traits. *Nature Genetics* (2021).
- 626 34. Ferreira, M.A. *et al.* Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. *Nat Genet* **49**, 1752-1757 (2017).
- 628 35. Chun, S. *et al.* Limited statistical evidence for shared genetic effects of eQTLs and autoimmune-disease-associated loci in three major immune-cell types. *Nat Genet* **49**, 630 600-605 (2017).
- 631 36. Consortium, G.T. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* **45**, 580-5 (2013).
- 633 37. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15-21 (2013).

- Robinson, M.D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. *Genome Biol* **11**, R25 (2010).
- 637 39. Vilhjalmsson, B.J. *et al.* Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. *Am J Hum Genet* **97**, 576-92 (2015).








<u>Figure 1.</u> GWAS of 52,630 COVID-19 positive cases vs. 704,016 COVID-19 negative or unknown controls identifies a novel association with a rare variant near *ACE2* that lowers gene expression and protects against COVID-19.


(A) Summary of association results for common (MAF>0.5%) and rare (MAF<0.5%) variants.




<u>Figure 1 (cont).</u> GWAS of 52,630 COVID-19 positive cases vs. 704,016 COVID-19 negative or unknown controls identifies a rare variant near ACE2 that lowers gene expression and protects against COVID-19.

- (B) Regional association plot centered around rs190509934 near ACE2.
- (C) Breakdown of association results across studies included in the meta-analysis of rs190509934.

D. <u>Normalized ACE2 expression</u>




Raw ACE2 expression




<u>Figure 1 (cont).</u> GWAS of 52,630 COVID-19 positive cases vs. 704,016 COVID-19 negative or unknown controls identifies a rare variant near ACE2 that lowers gene expression and protects against COVID-19.

(D) Association between rs190509934:C and ACE2 expression in liver measured in 2,035 individuals (80% female) from the GHS study.

A. Risk of hospitalization




B. Risk of severe disease




Percentile of genetic risk score (GRS)


<u>Figure 2.</u> Association between a 6-SNP genetic risk score (GRS) and risk of hospitalization (A) and severe disease (B) among COVID-19 cases of European ancestry (N=44,958).

A. AncestryDNA study





B. UK Biobank study






<u>Figure 3.</u> Association between a 6-SNP genetic risk score (GRS) and risk of severe disease among COVID-19 cases of European ancestry.






<u>Supplementary Figure 1</u>. Comparison of effect sizes across COVID-19 susceptibility and severity outcomes for six previously reported risk variants that validated in our study.

A. AncestryDNA study



B. UK Biobank study




Supplementary Figure 2. Association between a six-SNP genetic risk score (GRS) and risk of hospitalization among COVID-19 cases of European ancestry.

Lower Clinical Risk

Lower Genetic Risk


High Clinical Risk

High Genetic Risk




<u>Supplementary Figure 3.</u> Association between a 6-SNP and 12-SNP genetic risk score (GRS) and risk of hospitalization and severe disease among COVID-19 cases of European ancestry.

A. Risk of hospitalization




B. Risk of severe disease



AncestryDNA study


Admixed American ancestry

<u>Supplementary Figure 4.</u> Association between a six-SNP genetic risk score (GRS) and risk of hospitalization (A) and (B) severe disease among COVID-19 cases of Admixed American ancestry.



Supplementary Figure 5. Association between risk of severe disease among COVID-19 cases of European ancestry and genetic risk scores determined based on (i) variants that were reported in the literature and validated in this study (Literature.HGI.1var: rs73064425 in LZTFL1; Literature.HGI.5var: variants from our 6-SNP model, with the exception of rs73064425 in LZTFL1; Literature.HGI.6var: all six variants from our 6-SNP model); (ii) pruning and thresholding applied to results from the risk of infection phenotype reported by the HGI, using different association P-value and LD r2 thresholds; (iii) LDpred applied to risk of infection reported by the HGI, considering different ϱ parameters.

UK Biobank - European ancestry: Risk of severe disease among COVID 19+ cases, 6-SNP GRS model



Lower Genetic Risk

High Genetic Risk


Age < 65

Age ≥ 65

No Risk Factors

Risk Factors

<u>Supplementary Figure 6.</u> Association between risk of severe disease among COVID-19 cases of European ancestry from the UK Biobank study and combination of clinical risk factors, genetic risk (6-SNP GRS model) and age.



Supplementary Table 1. Breakdown of COVID-19 status across the four studies included in the analysis.

COVID-19	Positive qPCR or	ICD10 U07	Severe COVID-19	Negative qPCR			Sample size		
status	serology for SARS-CoV-2	diagnosis or hospitalization	(ventilation or death)	or serology test for SARS-CoV-2	AncestryDNA	UK Biobank	GHS	PMBB	Total
	Yes	Yes	Yes	Yes or No or NA	817	793	326	22	1,958
	Yes	Yes	No or NA	Yes or No or NA	1,016	2810	471	122	4,419
	Yes	No or NA	Yes	Yes or No or NA	0	0	0	0	0
	Yes	No or NA	No or NA	Yes or No or NA	29,093	11,613	4695	240	45,641
	No or NA	Yes	Yes	No or NA	0	187	0	0	187
Positive	No or NA	Yes	No or NA	No or NA	0	164	0	0	164
	No or NA	No or NA	Yes	No or NA	0	0	0	0	0
	No or NA	Yes	Yes	Yes	0	54	0	0	54
	No or NA	Yes	No or NA	Yes	0	202	0	5	207
	No or NA	No or NA	Yes	Yes	0	0	0	0	0
					Total = 30,926	Total =15,823	Total = 5492	Total = 389	Total = 52,630
Negative	No or NA	No or NA	No or NA	Yes	36,107	47,205	23,737	2556	109,605
Unknown	NA	No or NA	No or NA	NA	96,617	395,999	88,788	13,007	594,411
	_	Total			163,650	459,027	118,017	15,952	756,646

Supplementary Table 2. Demographics and clinical characteristics of study participants.

Demographics	COVID-1	9 Positive	Covid-19 Negative or
, .	Hospitalized	Not Hospitalized	Unknown
	AncestryDNA		
Total N	1818	29,093	132,724
AFR ancestry, n (%)	135 (7.34%)	1494 (5.14%)	5688 (4.29%)
AMR ancestry, n (%)	199 (10.95%)	3553 (12.21%)	13323 (10.04%)
EAS ancestry, n (%)	0 (0%)	110 (0.38%)	570 (0.43%)
EUR ancestry, n (%)	1484 (81.63%)	23869 (81.04%)	113882 (85.80%)
SAS ancestry, n (%)	<100 (0%)	<100 (0.23%)	261 (0.20%)
Average Age, y (% >60y)	57.84 (863)	50.1 (7940)	59.43 (48547)
Female, n (%)	726 (60.4%)	9870 (66.1%)	42909 (67.7%)
Hypertension, n (%)	670 (36.6%)	5402 (18.6%)	28912 (21.8%)
Cardiovascular Disease, n (%)	204 (11.1%)	1048 (3.6%)	6573 (5.0%)
Type 2 Diabetes, n (%)	392 (21.4%)	2330 (8.0%)	12432 (9.4%)
Chronic kidney disease, n (%)	<100 (5.0%)	323 (1.1%)	2123 (1.6%)
Asthma, n (%)	382 (20.8%)	3861 (13.3%)	18256 (13.8%)
COPD, n (%)	125 (6.8%)	523 (1.8%)	3563 (2.7%)
	UK Biobank		
Total N	4188	11,613	443,204
AFR ancestry, n (%)	148 (3.53%)	472 (4.06%)	8804 (1.99%)
EAS ancestry, n (%)	0 (0%)	64 (0.55%)	2209 (0.50%)
EUR ancestry, n (%)	3884 (92.74%)	10470 (90.16%)	422309 (95.29%)
SAS ancestry, n (%)	156 (3.72%)	607 (5.23%)	9882 (2.23%)
Average Age, y (% >60y)	61 (52.3%)	51 (20.2%)	57 (37.2%)
Female, n (%)	1838 (43.9%)	6410 (55.2%)	244345 (55.1%)
Hypertension, n (%)	1851 (44.2%)	2407 (20.7%)	102820 (23.2%)
Cardiovascular Disease, n (%)	553 (13.2%)	566 (4.8%)	25998 (5.9%)
Type 2 Diabetes, n (%)	757 (18.0%)	766 (6.6%)	26743 (6%)
Chronic kidney disease, n (%)	280 (6.7%)	190 (1.6%)	8546 (1.9%)
Asthma, n (%)	829 (19.8%)	1784 (15.4%)	62740 (14.1%)
COPD, n (%)	392 (9.3%)	250 (2.1%)	10762 (2.4%)
	GHS		
Total N	773	4827	116734
AFR ancestry, n (%)	0 (0%)	112 (2.32%)	3050 (2.61%)

AMR ancestry, n (%)	0 (0%)	80 (1.65%)	1307 (1.11%)
EUR ancestry, n (%)	773 (100%)	4503 (93.28%)	108168 (92.66%)
Average Age, y (% >60y)	68.68 (76.06%)	52.20 (33.39%)	55.41 (43.43%)
Female, n (%)	393 (50.84%)	3129 (66.64%)	70456 (62.61%)
Hypertension, n (%)	603 (78.00%)	2191 (46.66%)	54881 (48.77%)
Cardiovascular Disease, n (%)	328 (42.43%)	653 (13.90%)	17395 (15.45%)
Type 2 Diabetes, n (%)	348 (45.01%)	1049 (22.34%)	24152 (21.46%)
Chronic kidney disease, n (%)	298 (38.55%)	519 (11.05%)	14534 (12.91%)
Asthma, n (%)	74 (9.57%)	381 (8.11%)	7146 (6.35%)
COPD, n (%)	192 (24.83%)	376 (8.00%)	11028 (9.80%)
	PMBB		
Total N	132	240	15563
AFR ancestry, n (%)	132 (100%)	217 (90.42%)	8564 (55.03%)
EUR ancestry, n (%)	0 (0%)	23 (9.58%)	6999 (44.97%)
Average Age, y (% >60y)	61.77 (58.33%)	50.45 (27.50%)	63.26 (61.95%)
Female, n (%)	69 (52.27%)	174 (72.50%)	8121 (52.18%)
Hypertension, n (%)	113 (85.61%)	141 (58.75%)	9466 (60.82%)
Cardiovascular Disease, n (%)	40 (30.30%)	34 (14.17%)	4842 (31.11%)
Type 2 Diabetes, n (%)	90 (68.18%)	70 (29.17%)	4546 (29.21%)
Chronic kidney disease, n (%)	74 (56.06%)	26 (10.83%)	3507 (22.53%)
Asthma, n (%)	29 (21.97%)	52 (21.67%)	2189 (14.07%)
COPD, n (%)	26 (19.70%)	15 (6.25%)	1706 (10.96%)

Supplementary Table 3. Definitions used for the seven COVID-19 phenotypes analyzed.

Broad phenotype	Phonotine	Case/control	• •	Definition			Sample siz	e with geneti	c data	
category	Phenotype	group	COVID-19 status	Hospitalized	Severe disease	AncestryDNA	UK Biobank	GHS	PMBB	Total
	COVID-19 positive	Cases	Positive	Yes, No or NA	Yes, No or NA	30,926	15,823	5,492	389	52,630
	COVID-19 negative or unknown	Controls	Negative or unknown	No or NA	No or NA	132,724	443,204	112,525	15,563	704,016
	COVID-19 positive	Cases	Positive	Yes, No or NA	Yes, No or NA	30,926	15,823	5,492	389	52,630
	vs. COVID-19 negative	Controls	Negative	No or NA	No or NA	36,107	47,205	23,737	2,556	109,605
Risk of infection	COVID-19 positive and not hospitalized	Cases	Positive	No	No	29,093	11,613	4,695	240	45,641
RISK OF Infection	vs. COVID-19 negative or unknown	Controls	Negative or unknown	No or NA	No or NA	132,724	443,204	112,525	15,563	704,016
	COVID-19 positive and hospitalized	Cases	Positive	Yes (or death)	Yes, No or NA	1,818	4,188	773	132	6,911
	vs. COVID-19 negative or unknown	Controls	Negative or unknown	No or NA	No or NA	131,893	440,995	108,168	8,564	689,620
	COVID-19 positive and severe	Cases	Positive	Yes, No or NA	Yes	810	1,028	321	25	2,184
	vs. COVID-19 negative or unknown	Controls	Negative or unknown	No or NA	No or NA	131,893	440,995	108,168	8,564	689,620
	COVID-19 positive and hospitalized	Cases	Positive	Yes (or death)	Yes, No or NA	1,818	4,188	773	132	6,911
Risk of adverse outcomes	Vs. COVID-19 positive and not hospitalized	Controls	Positive	No	No	28,916	11,549	4,503	217	45,185
amongst infected individuals	COVID-19 positive and severe	Cases	Positive	Yes, No or NA	Yes	810	1,028	321	25	2,184
	vs. COVID-19 positive and not hospitalized	Controls	Positive	No	No	28,916	11,549	4,503	217	45,185

Supplementary Table 4. Genomic inflation factor (lambda) across the seven COVID-19 phenotypes analyzed.

Index	Dhonotyno	Study	N aggag	N controls	Total N	Common variants	(MAF>0.5%)	Rare variants	(MAF<0.5%)
muex	Phenotype	Study	N cases	N controls	I otal N	N variants	Lambda	N variants	Lambda
		Meta-analysis	52630	704016	756646	12659604	1.054	76347805	1.011
		ANCESTRY Freeze Four EUR	25353	113882	139235	9114485	1.032	17505860	1.021
		UKB 500K EUR	14354	422309	436663	10518951	1.034	41557338	1.038
		GHS Freeze 145 EUR	5276	108168	113444	10517411	1.013	31213671	1.078
		ANCESTRY Freeze Four AMR	3752	12323	16075	10360579	1.126	16342242	1.142
		ANCESTRY Freeze Four AFR	1629	5688	7317	16651249	1.083	7924824	1.111
	COVID19 positive	UKB 500K SAS	763	9882	10645	11223467	1.047	16126339	1.147
1	VS	UKB 500K AFR	620	8804	9424	19365480	1.028	23403726	1.126
	COVID19 negative or unknown	UPENN-PMBB Freeze One TOPMED AFR	349	8564	8913	19201924	0.993	24334265	0.877
		GHS Freeze 145 AFR	128	3050	3178	19261006	0.793	13222396	0.775
		ANCESTRY Freeze Four EAS	120	570	690	8287783	0.955	388659	1.276
		GHS Freeze 145 AMR	88	1307	1395	13559291	0.784	5975072	0.804
		UKB_500K_EAS	86	2209	2295	9472040	0.994	5274937	0.808
		ANCESTRY Freeze Four SAS	<100	261	333	8772668	0.772	86	0.772
		UPENN-PMBB Freeze One TOPMED EUR	40	6999	7039	10569481	0.914	11542106	0.189
		Meta-analysis	52630	109605	162235	15917507	1.018	48430743	1.047
		ANCESTRY Freeze Four EUR	25353	30667	56020	9116923	1.069	17300691	1.065
		UKB 500K EUR	14354	44903	59257	10521738	1.031	31741985	1.05
		GHS Freeze 145 EUR	5276	22848	28124	10518718	1.021	26548178	1.082
		ANCESTRY Freeze Four AMR	3752	3403	7155	10409037	1.056	12259804	1.071
		ANCESTRY Freeze Four AFR	1629	1783	3412	16657740	1.037	5856801	1.063
	COVID19 positive	UKB 500K SAS	763	1104	1867	11217149	0.986	4212996	1.03
2	VS	UKB 500K AFR	620	1029	1649	19377829	0.988	6949159	1.032
	COVID19 negative	UPENN-PMBB Freeze One TOPMED AFR	349	1804	2153	19210279	1.001	9238302	1.159
	8	GHS Freeze 145 AFR	128	583	711	19220711	0.684	2145450	1.005
		ANCESTRY Freeze Four EAS	120	174	294	7368136	0.816	NA	NA
		GHS Freeze 145 AMR	88	306	394	12615699	0.625	NA	NA
		UKB 500K EAS	86	169	255	8096105	0.767	NA	NA
		ANCESTRY Freeze Four SAS	<100	<100	152	7499011	0.477	NA	NA
		UPENN-PMBB Freeze One TOPMED EUR	40	752	792	10649166	0.902	1084967	0.686
		Meta-analysis	45641	704016	749657	12664016	1.049	76053657	0.971
		ANCESTRY Freeze Four EUR	23869	113882	137751	9114352	1.033	17505215	1.02
		UKB 500K EUR	10470	422309	432779	10518900	1.027	41512665	1.004
		GHS Freeze 145 EUR	4503	108168	112671	10517274	1.015	31211655	1.112
		ANCESTRY Freeze Four AMR	3553	12323	15876	10359235	1.126	16286078	1.142
		ANCESTRY Freeze Four AFR	1494	5688	7182	16650531	1.080	7876530	1.119
	COVID19 positive not hospitalized	UKB 500K SAS	607	9882	10489	11224048	1.036	16007835	1.085
3	VS	UKB 500K AFR	472	8804	9276	19365078	1.037	23196596	1.048
	COVID19 negative or unknown	UPENN-PMBB Freeze One TOPMED AFR	217	8564	8781	19201513	0.981	24110114	0.655
		GHS Freeze 145 AFR	112	3050	3162	19259910	0.798	13175822	0.706
		ANCESTRY Freeze Four EAS	110	570	680	8277196	0.937	370881	1.238
		GHS Freeze 145 AMR	80	1307	1387	13555149	0.805	5935171	0.752
		ANCESTRY Freeze Four SAS	<100	261	328	8746716	0.734	59	0.737
		UKB 500K EAS	64	2209	2273	9469792	1.011	5218675	0.653
		UPENN-PMBB Freeze One TOPMED EUR	23	6999	7022	10568880	0.842	11520379	0.103
		Meta-analysis	6911	689620	696531	12311356	1.019	72100390	0.774
		UKB 500K EUR	3884	422309	426193	10518717	1.029	41438313	0.869

		ANCESTRY Freeze Four EUR	1484	113882	115366	9113935	1.020	17492079	1.095
	COVID19 positive hospitalized	GHS Freeze 145 EUR	773	108168	108941	10517626	0.989	31200896	0.679
4	VS	ANCESTRY Freeze Four AMR	199	12323	12522	10355552	0.954	15145563	0.66
	COVID19 negative or unknown	UKB 500K SAS	156	9882	10038	11226298	0.956	15643828	0.594
	č	UKB_500K_AFR	148	8804	8952	19364991	0.959	22729568	0.524
		ANCESTRY Freeze Four AFR	135	5688	5823	16650183	0.845	7301363	0.704
		UPENN-PMBB Freeze One TOPMED AFR	132	8564	8696	19203151	0.954	23970759	0.463
		Meta-analysis	2184	689620	691804	12317578	0.996	71887891	0.436
		UKB 500K EUR	953	422309	423262	10518693	1.017	41399045	0.518
		ANCESTRY Freeze Four EUR	667	113882	114549	9113896	1.010	17491621	0.797
	COVID19 positive severe	GHS Freeze 145 EUR	321	108168	108489	10517572	0.944	31199381	0.337
5	VS	ANCESTRY Freeze Four AMR	<100	12323	12404	10356352	0.929	15099237	0.371
	COVID19 negative or unknown	ANCESTRY Freeze Four AFR	<100	5688	5750	16648952	0.925	7269674	0.481
	S	UKB_500K_AFR	43	8804	8847	19365845	0.985	22580462	0.17
		UKB 500K SAS	32	9882	9914	11226767	0.918	15544218	0.168
		UPENN-PMBB Freeze One TOPMED AFR	25	8564	8589	19201950	0.910	23788706	0.093
		Meta-analysis	6911	45185	52096	17736142	0.980	24498210	1.056
		UKB_500K_EUR	3884	10470	14354	10524169	1.040	16832015	1.071
		ANCESTRY Freeze Four EUR	1484	23869	25353	9117639	1.011	15595929	1.148
	COVID19 positive hospitalized	GHS Freeze 145 EUR	773	4503	5276	10521676	1.008	8477328	1.132
6	VS	ANCESTRY Freeze Four AMR	199	3553	3752	10392795	1.006	8906919	1.083
	COVID19 positive not hospitalized	UKB 500K SAS	156	607	763	11125523	0.881	900209	1.018
		UKB_500K_AFR	148	472	620	19346132	0.963	1173739	1.121
		ANCESTRY Freeze Four AFR	135	1494	1629	16632746	0.879	3878224	1.088
		UPENN-PMBB Freeze One TOPMED AFR	132	217	349	17386629	0.878	NA	NA
		Meta-analysis	2184	45185	47369	17565432	0.977	22301026	0.981
		UKB 500K EUR	953	10470	11423	10524284	1.046	14265668	1.086
		ANCESTRY Freeze Four EUR	667	23869	24536	9117378	1.028	15460239	0.885
	COVID19 positive severe	GHS Freeze 145 EUR	321	4503	4824	10521257	0.902	7888063	0.971
7	VS	ANCESTRY Freeze Four AMR	<100	3553	3634	10395661	0.993	8745342	0.685
	COVID19 positive not hospitalized	ANCESTRY Freeze Four AFR	<100	1494	1556	16630281	0.978	3750324	0.792
		UKB 500K AFR	43	472	515	19296565	0.892	266926	0.693
		UKB 500K SAS	32	607	639	11034836	0.814	467149	0.548
		UPENN-PMBB Freeze One TOPMED AFR	25	217	242	15603727	0.998	NA	NA

Supplementary Table 5. Eight variants associated with COVID-19 susceptibility in previous GWAS.

Locus index	Independent signal index	Reference (PMID)	First author	Phenotype	rs ID	hg38	Nearest gene	Effect allele	Locus	Odds Ratio	LCI	UCI	P-value	N cases	N controls	Top independent association in locus
1	1	33307546	Pairo-Castineira	covid19 severe vs negative or unknown	rs73064425	3:45859597:C:T	LZTFL1	T	3p21.31	2.14	1.88	2.45	4.77E-30	1676	8380	1
1	2	33888907	Shelton	covid test positive vs negative	rs2531743	3:45796808:G:A	SLC6A20	G	3p21.31	0.917	0.89	0.94	7.60E-10	12972	101268	1
2	1	33307546	Pairo-Castineira	covid19 severe vs negative or unknown	rs143334143	6:31153649:G:A	CCHCR1	A	6p21.33	1.85	1.61	2.13	8.82E-18	1676	8380	1
3	1	33888907	Shelton	covid test positive vs negative	rs9411378	9:133270015:A:C	ABO	A	9q34.2	1.17	1.12	1.20	5.30E-20	12972	101268	1
4	1	33307546	Pairo-Castineira	covid19 severe vs negative or unknown	rs10735079	12:112942203:G:A	OAS3	A	12q24.13	1.29	1.18	1.42	1.65E-08	1676	8380	1
5	1	33307546	Pairo-Castineira	covid19 severe vs negative or unknown	rs2109069	19:4719431:G:A	DPP9	A	19p13.3	1.36	1.25	1.48	3.98E-12	1676	8380	1
6	1	33307546	Pairo-Castineira	covid19 severe vs negative or unknown	rs74956615	19:10317045:T:A	RAVER1	A	19p13.2	1.59	1.35	1.87	2.31E-08	1676	8380	1
7	1	33307546	Pairo-Castineira	covid19 severe vs negative or unknown	rs2236757	21:33252612:A:G	IFNAR2	A	21q22.1	1.28	1.17	1.41	5.00E-08	1676	8380	1

Supplementary Table 6. Sample overlap between our study and those queried to identify variants associated with COVID-19 susceptibility in previous GWAS.

~ upprement	,	F		our sound und those queried to ruentry variables appointed with 55 viz 15 susceptibility in previous						
First author	Reference (PMID)	N cases	N controls	Sample overlap with our study						
				Three studies with minimal or no sample overlap with our study						
	(eight var	iants selected	for replication wi	th five susceptibility phenotypes: in/near LZTFL1, SLC6A20, MHC, ABO, OAS3, DPP9, RAVER1 and IFNAR2)						
Ellinghaus	32558485	1,610	2,205	No known overlap						
Pairo-Castineira	33307546	1,676	8,380	~1% of samples from our analysis of UKB were included as controls in this study						
Shelton	33888907	15,434	1,035,598	No known overlap						
				One study with substantial sample overlap with our study						
(Four	variants associated wi	ith reported in	fection [phenotype	[2"] selected for look-up in our independent analysis of severity among cases: in/near RPL24, DNAH5, FOXP4 and PLEKHA4)						
HGI (freeze 5)	il (freeze 5) NA 49,562 1.7 million ~100% of samples from UKB, GHS and UPENN, and ~60% from AncestryDNA contributed to HGI, but using an earlier phenotype freeze									

Supplementary Table 7. Comparison of effect sizes between ancestries for the novel ACE2 risk variant.

Locus, nearest gene	rs ID	hg38	Effect allele	Phenotype	Ancestry	Odds Ratio (95% CI)	P-value	N cases with 0 1 2 copies of the effect allele	N controls with 0 1 2 copies of the effect allele	Effect allele frequency	Cross-ancestry heterogeneity test P-value
Xp22.2				COVID19 positive vs	AFR AMR	0.578[0.373,0.894] 0.792[0.431,1.456]	0.014	2713 12 1 3830 10 0	25905 146 55 13577 44 9	0.005 0.002	
ACE2	rs190509934	23:15602217:T:C	С	COVID19 negative or unknown	EUR	0.606[0.516,0.711]	8.80E-10	44930 87 6	648877 1835 646	0.002	0.676
					SAS	0.500[0.323,0.773]	0.0018	821 13 1	9815 226 102	0.020	

Supplementary Table 8. Association results in the UK Biobank study between six established clinical risk factors for COVID-19 and (i) the novel risk variant in ACE2; (ii) the six published risk variants for COVID-19 that validated in this study; and (iii) the two novel risk variants identified in the HGI analysis of C2 and that we found to also associate with disease severity.

Nearest gene	Variant	Effect allele	Disease Disease	Odds Ratio	P-value	Effect allele frequency	N cases	N controls
			(i) Novel risk var	riant in ACE2				
			Coronary artery disease	0.917[0.798,1.054]	0.2245	0.0027	28605	254598
			Kidney disease	0.927[0.808,1.064]	0.2800	0.0030	35472	211418
ACE2	23:15602217:T:C	С	Hypertension	0.899[0.821,0.984]	0.0210	0.0030	105117	269090
ACE2	23:13002217:1:C		COPD	0.904[0.739,1.105]	0.3200	0.0030	12839	372779
			Asthma	1.016[0.896,1.151]	0.8100	0.0030	39372	343873
			Type-2 diabetes	0.957[0.831,1.103]	0.5500	0.0030	25722	433026
			(ii) Six published risk variants	s that validated in this stu	ıdy			
			Coronary artery disease	0.997[0.981,1.014]	0.7500	0.4070	38269	416904
			Kidney disease	1.000[0.983,1.018]	0.9700	0.4160	35472	211418
SLC6A20	3:45796808:G:A	G	Hypertension	0.995[0.984,1.007]	0.4100	0.4160	105117	269090
SLC 0A20	3:43/90808:G:A	6	COPD	1.011[0.984,1.038]	0.4300	0.4160	12839	372779
			Asthma	0.993[0.978,1.009]	0.3800	0.4160	39372	343873
			Type-2 diabetes	0.999[0.980,1.018]	0.9000	0.4160	25722	433026
			Coronary artery disease	0.986[0.957,1.017]	0.3700	0.0700	38269	416904
LZTFL1			Kidney disease	1.018[0.985,1.052]	0.2900	0.0690	35472	211418
	3:45859597:C:T	T	Hypertension	1.003[0.982,1.025]	0.7700	0.0690	105117	269090
LZIFLI		T	COPD	1.053[1.002,1.107]	0.0410	0.0690	12839	372779
			Asthma	1.026[0.996,1.056]	0.0940	0.0690	39372	343873
			Type-2 diabetes	1.002[0.966,1.039]	0.9200	0.0690	25722	433026
			Coronary artery disease	1.048[1.016,1.081]	0.0030	0.0650	38269	416904
			Kidney disease	1.016[0.982,1.051]	0.3500	0.0650	35472	211418
CCHCD1	6 21152640 G A		Hypertension	0.989[0.968,1.011]	0.3400	0.0650	105117	269090
CCHCR1	6:31153649:G:A	A	COPD	0.999[0.949,1.052]	0.9800	0.0650	12839	372779
			Asthma	0.913[0.885,0.941]	6.80E-09	0.0650	39372	343873
			Type-2 diabetes	1.083[1.045,1.123]	1.50E-05	0.0660	25722	433026
			Coronary artery disease	1.022[1.004,1.040]	0.0180	0.2550	38269	416904
			Kidney disease	0.963[0.945,0.982]	0.0001	0.2590	35472	211418
4BO	0.122271102 T.C	T	Hypertension	0.990[0.978,1.003]	0.1400	0.2570	105117	269090
ABO	9:133271182:T:C	T	COPD	1.009[0.980,1.039]	0.5500	0.2570	12839	372779
			Asthma	1.012[0.995,1.030]	0.1800	0.2570	39372	343873
			Type-2 diabetes	1.042[1.021,1.064]	0.0001	0.2570	25722	433026
			Coronary artery disease	1.009[0.992,1.025]	0.3100	0.3230	38269	416904
			Kidney disease	0.982[0.964,1.000]	0.0460	0.3200	35472	211418

•	1			T. T				
DPP9	19:4719431:G:A	A	Hypertension	0.998[0.987,1.010]	0.7700	0.3200	105117	269090
Dily	19.4/19431.G.A	Λ	COPD	0.992[0.965,1.019]	0.5600	0.3200	12839	372779
			Asthma	1.000[0.984,1.016]	0.9900	0.3200	39372	343873
			Type-2 diabetes	1.004[0.984,1.024]	0.7200	0.3200	25722	433026
			Coronary artery disease	1.012[0.994,1.029]	0.1900	0.2810	38269	416904
			Kidney disease	1.006[0.987,1.025]	0.5400	0.2860	35472	211418
IFNAR2	21,22252(12,4,6		Hypertension	1.008[0.996,1.021]	0.1800	0.2870	105117	269090
IFNAR2	21:33252612:A:G	A	COPD	0.992[0.965,1.021]	0.6000	0.2870	12839	372779
			Asthma	1.011[0.995,1.028]	0.1900	0.2870	39372	343873
			Type-2 diabetes	1.013[0.992,1.033]	0.2300	0.2870	25722	433026
	(iii) Two novel risk	variants id	entified in the HGI analysis of	C2 and that we found to	also associate i	vith disease so	everity	
			Coronary artery disease	1.006[0.990,1.022]	0.4900	0.3550	38269	416904
			Kidney disease	1.004[0.987,1.022]	0.6300	0.3550	35472	211418
RPL24	3:101705614:T:C	С	Hypertension	1.012[1.001,1.024]	0.0400	0.3540	105117	269090
KI L24	3.101/03014.1.C		COPD	1.004[0.978,1.031]	0.7400	0.3550	12839	372779
			Asthma	0.980[0.965,0.996]	0.0120	0.3550	39372	343873
			Type-2 diabetes	0.991[0.973,1.010]	0.3700	0.3550	25722	433026
			Coronary artery disease	0.977[0.924,1.033]	0.4100	0.0210	38269	416904
			Kidney disease	0.989[0.933,1.050]	0.7300	0.0210	35472	211418
FOXP4	6:41534945:A:C	С	Hypertension	0.996[0.958,1.035]	0.8200	0.0210	105117	269090
ΓΟΛΓ4	0.41334343.A.C		COPD	0.982[0.897,1.076]	0.7000	0.0210	12839	372779
			Asthma	0.976[0.926,1.030]	0.3800	0.0210	39372	343873
			Type-2 diabetes	1.009[0.946,1.077]	0.7800	0.0210	25722	433026

Supplementary Table 9. Association between two severity phenotypes and a novel risk variant for COVID-19 near ACE2 identified in this study.

	ocus, est gene	rs ID	hg38	Phenotype	Effect allele	Odds Ratio* [95% CI]	P-value	N cases with 0 1 2 copies of the effect allele	N controls with 0 1 2 copies of the effect allele	Effect allele frequency	N cases	N controls	Cross-study heterogeneity test P-value
XI	22.2	rs190509934	23:15602217:T:C	COVID19 positive hospitalized vs COVID19 positive not hospitalized	C	0.694[0.419,1.150]	1.57E-01	6766 13 0	44854 106 8	0.001	6779	44968	0.222
A	CE2	18190309934	23:13602217:1:C	COVID19 positive severe vs COVID19 positive not hospitalized	C	0.544[0.210,1.408]	2.10E-01	2157 2 0	44854 106 8	0.001	2159	44968	0.916
* Esti	* Estimated based on trans-ancestry inverse-variance meta-analysis across UKB, AncestryDNA, GHS and UPENN-PMBB.												

Supplementary Table 10. Published gene expression datasets used to identify sentinel expression quantitative trait loci (eQTL) that co-localized (LD r2>0.8) with sentinel GWAS variants.

First author Tissue/cell type Sample size MACROPHAGES-IFNg 86 MACROPHAGES-IFNg-salmonella 86 Alasoo 29379200 MACROPHAGES-naive 86 MACROPHAGES-salmonella Andiappan 26259071 NEUTROPHILS 114 DENDRITIC-NotInfected 65 Barreiro 22233810 DENDRITIC-TBInfected 65 WHOLE-BLOOD 922 Battle WHOLE-BLOOD-ase 922 WHOLE-BLOOD-splice 922 LCLS 506 Brown SKIN 471 WHOLE-BLOOD 242 Brumpton 27155841 LCLS 356 PBMCS-baseline 98 Caliskan 25874939 PBMCS-rhinovirus PBMCS-rhinovirus-reQTL 98 CD4TCELLS Up to 197 Chen 27863251 MONOCYTES Up to 197 NEUTROPHILS Up to 197 LUNG Up to 147 Chiang 2836903 SKIN Up to 147 WHOLEBLOOD Up to 147 Davenport 2016 26917434 LEUCOCYTES 265 WHOLEBLOOD 157 Davenport 2018 30340504 WHOLEBLOOD-IFN-interaction 157 LCLS 75 Dimas TCELLS 75 Di Narzo 27336838 149 WHOLE-BLOOD LESIONAL-SKIN 57 Ding 21129726 NORMAL-SKIN 53 UNINVOLVED-SKIN 53 Dixon 17873877 LCLS 400 BCELLS 283 Fairfax 2012 2244696 283 MONOCYTES MONOCYTES-IFN 367 MONOCYTES-LPS2 261 Fairfax 2014 24604202 322 MONOCYTES-LPS24 MONOCYTES-NAIVE 414 Fehrmann 21829388 WHOLE-BLOOD 1469 Tconv 65 2461077 Ferraro 65 Tregs Franco 23878721 WHOLE-BLOOD-Influenza 247 Lappalainen 24037378 LCLS 373 LCLS 856 Grundberg 22941192 SKIN 856 GTEx v8 49 individual tissues 73-706 Hao 23209423 LUNG 1111 LCLs 368 Huang 25951796 PBMCs 240 SKIN 110 28165122 WHOLE-BLOOD 4896 Jansen WHOLE-BLOOD 5257 Joahnes CD4TCELLS 293 Kasela 28248954 CD8TCELLS 293 MONOCYTES-LPS6H 134 MONOCYTES-LPS90 134 KimHellmuth MONOCYTES-MDP6H 134 MONOCYTES-MDP90 134

MONOCYTES-RNA6H

134

		MONOCYTES-Baseline	137
Kim	25327457	MONOCYTES-Differential	137
		MONOCYTES-LPS	137
Kukurba	27197214	WHOLE-BLOOD	922
		DENDRITIC-Baseline	528
		DENDRITIC-Flu	342
		DENDRITIC-Flu-delta	342
Lee	24604203	DENDRITIC-IFNb	284
		DENDRITIC-IFNb-delta	284
		DENDRITIC-LPS	356
	******	DENDRITIC-LPS-delta	356
LloydJones	28065468	WHOLE-BLOOD	2765
Luo	26102239	SMALL-AIRWAYS	105
		BCELLS	323
	29930244	CD4TCELLS	323
Momozawa	29930244	CD8TCELLS	323
		GRANULOCYTES	323
		MONOCYTES	323
Murphy	20833654	CD4-TCELLS	200
Naranbhai	26151758	NEUTROPHILS	101
		MACROPHAGES-baseline	95
		MACROPHAGES-baseline-asQTL	95
		MACROPHAGES-listeria	95
Nedelec	27768889	MACROPHAGES-listeria-asQTL	95
		MACROPHAGES-listeria-reQTL	95
		MACROPHAGES-salmonella	95
		MACROPHAGES-salmonella-asQTL	95
		MACROPHAGES-salmonella-reQTL	95
Pala	28394350	LEUCOCYTES	624
		BCELLS	80
_		CD4-TCELLS	121
Peters	27015630	CD8-TCELLS	108
		MONOCYTES	124
		NEUTROPHILS	121
Qiu 2011	21949713	SPUTUM	131
Qiu 2014	24770851	LCLS-steroids	117
		MONOCYTES-baseline	100
01	277/0000	MONOCYTES-IAV	100
Quach	27768888	MONOCYTES-LPS	100
		MONOCYTES-Pam3CSK4	100
	<u> </u>	MONOCYTES-R848	100
Raj	24786080	CD4-TCELLS	407
	1	MONOCYTES	401
		BCELLS	45
		CD4TCELLS	45
		CD8TCELLS	45
vande-Wii	29610479	DENDRITIC	45 45
vanderWijst	290104/9	MONOCYTES	
		MONOCYTES - classical	45 45
		MONOCYTES-nonclassical	45
		NKCELLS PBMCS	45
Vosa	BioRxiv	WHOLE-BLOOD+PBMCS	31684
Walsh	27140173	WHOLE-BLOOD WHOLE-BLOOD	377
Westra	24013639	WHOLE-BLOOD WHOLE-BLOOD	5311
Yao	28285768	WHOLE-BLOOD WHOLEBLOOD	5257
1 80	20203/08	CD4-TCELLS-48h328	348
		CD4-TCELLS-48hTh17	348
Ye	25214635	CD4-TCELLS-48iTil17 CD4-TCELLS-4h328	348
16	20214000	CD4-TCELLS-4hIFNb	348
i		CD4-TCELLS-4nif No	348
	1		1490
Zallar	20502602	MONOCYTES	
Zeller	20502693	MONOCYTES WHOLEPLOOD even primary	
		WHOLEBLOOD-exon-primary	2116
Zeller Zhernakova	20502693 27918533	WHOLEBLOOD-exon-primary WHOLEBLOOD-exonratio-primary	2116 2116
		WHOLEBLOOD-exon-primary	2116

Supplementary Table 11. Association between systolic and diastolic blood pressure in Europeans of the UK Biobank study and (i) the rare non-coding variant near ACE2 that was found to be associated with COVID-19 risk; and (ii) a burden of ultra-rare coding variants in ACE2 that are predicted to be loss-of-function.

Variant	Effect allele	Phenotype	Effect[95% CI]	P-value	N individuals with 0 1 2 copies of the effect allele	Effect allele frequency
23:15602217:T:C		Systolic_blood_pressure	0.009[-0.022,0.041]	5.60E-01	406539 1179 493	3.00E-03
23.13002217.1.C		Diastolic_blood_pressure	0.017[-0.017,0.051]	3.30E-01	406543 1179 493	3.00E-03
Burden of predicted loss-of-	Minor allele for any	Systolic_blood_pressure	0.219[-0.031,0.469]	8.60E-02	408174 33 4	5.00E-05
function (pLOF) variants	pLOF variant	Diastolic_blood_pressure	0.195[-0.070,0.461]	1.50E-01	408178 33 4	5.00E-05

Locus, earest gene	rs ID	hg38	Phenotype	Effect allele	Odds Ratio* [95% CI]	P-value	N cases with 0 1 2 copies of the effect allele	N controls with 0 1 2 copies of the effect allele	Effect allele frequency	N cases	N controls	Heterozygote Odds Ratio** [95% CI]	Homozygote Odds Ratio** [95% CI]	Cross-study heterogeneity t P-value
			COVID19_positive_hospitalized_vs_COVID19_negative_or_unknown	G	0.971[0.937,1.006]	1.07E-01	2398 3345 1168	234336 336160 119124	0.416	6911	689620	0.971[0.921,1.023]	0.954[0.889,1.024]	0.1686
2 21 21			COVID19 positive_not_hospitalized_vs_COVID19_negative_or_unknown	G	0.954[0.940,0.969]	8.21E-10	16157 22128 7356	240080 342626 121310	0.415	45641	704016	0.966[0.946,0.988]	0.913[0.886,0.94]	0.6444
3p21.31 SLC6A20	rs2531743	3:45796808:G:A	COVID19_positive_severe_vs_COVID19_negative_or_unknown	G	0.917[0.861,0.977]	7.19E-03	776 1072 336	234336 336160 119124	0.416	2184	689620	0.957[0.872,1.05]	0.841[0.739,0.956]	0.5430
SLC0A20			COVID19_positive_vs_COVID19_negative	G	0.943[0.927,0.958]	2.95E-12	18592 25509 8529	36660 53558 19387	0.416	52630	109605	0.951[0.929,0.974]	0.89[0.861,0.919]	0.6468
			COVID19_positive_vs_COVID19_negative_or_unknown	G	0.958[0.945,0.971]	1.19E-09	18592 25509 8529	240080 342626 121310	0.415	52630	704016	0.968[0.948,0.987]	0.919[0.894,0.945]	0.6063
			COVID19_positive_hospitalized_vs_COVID19_negative_or_unknown	T	1.289[1.211,1.371]	9.71E-16	5713 1127 71	592971 92456 4193	0.073	6911	689620	1.285[1.204,1.371]	1.699[1.336,2.16]	0.0306
221.21			COVID19_positive_not_hospitalized_vs_COVID19_negative_or_unknown	T	1.017[0.990,1.045]	2.25E-01	39073 6308 260	605892 93863 4261	0.073	45641	704016	1.03[1.001,1.06]	0.899[0.79,1.024]	0.5419
3p21.31 LZTFL1	rs73064425	3:45859597:C:T	COVID19_positive_severe_vs_COVID19_negative_or_unknown	T	1.581[1.427,1.752]	2.16E-18	1732 421 31	592971 92456 4193	0.073	2184	689620	1.585[1.423,1.766]	2.591[1.808,3.712]	0.5770
LZIFLI			COVID19_positive_vs_COVID19_negative	T	1.067[1.035,1.100]	2.67E-05	44855 7443 332	94427 14495 683	0.074	52630	109605	1.076[1.043,1.11]	0.958[0.836,1.098]	0.8732
			COVID19_positive_vs_COVID19_negative_or_unknown	T	1.052[1.026,1.079]	7.32E-05	44855 7443 332	605892 93863 4261	0.073	52630	704016	1.063[1.035,1.091]	1.001[0.891,1.124]	0.6960
			COVID19_positive_hospitalized_vs_COVID19_negative_or_unknown	A	1.103[1.035,1.176]	2.53E-03	5839 1017 55	592380 93262 3978	0.073	6911	689620	1.103[1.031,1.179]	1.379[1.055, 1.803]	0.4370
c 21 22			COVID19 positive_not_hospitalized_vs_COVID19_negative_or_unknown	A	1.021[0.995,1.048]	1.07E-01	38299 7008 334	604383 95543 4090	0.074	45641	704016	1.039[1.011,1.068]	1.021[0.909,1.147]	0.7970
6p21.33 CCHCR1	rs143334143	6:31153649:G:A	COVID19_positive_severe_vs_COVID19_negative_or_unknown	A	1.175[1.054,1.310]	3.63E-03	1814 347 23	592380 93262 3978	0.073	2184	689620	1.166[1.039,1.308]	1.727[1.143,2.611]	0.8028
CHCKI			COVID19_positive_vs_COVID19_negative	A	1.057[1.026,1.088]	2.00E-04	44198 8040 392	93495 15427 683	0.079	52630	109605	1.065[1.033,1.098]	1.104[0.969,1.256]	0.4270
			COVID19_positive_vs_COVID19_negative_or_unknown	A	1.032[1.008,1.058]	9.47E-03	44198 8040 392	604383 95543 4090	0.074	52630	704016	1.047[1.021,1.074]	1.069[0.96,1.191]	0.5346
			COVID19_positive_hospitalized_vs_COVID19_negative_or_unknown	T	1.096[1.054,1.139]	4.06E-06	3743 2658 510	384940 259919 44761	0.253	6911	689620	1.077[1.024,1.132]	1.221[1.112,1.34]	0.7870
0.242	rs879055593		COVID19 positive_not_hospitalized_vs_COVID19_negative_or_unknown	T	1.098[1.081,1.116]	7.88E-30	24427 18060 3154	393656 264837 45523	0.254	45641	704016	1.114[1.091,1.137]	1.156[1.111,1.203]	0.3500
9q34.2 ABO	(proxy for	9:133271182:T:C	COVID19_positive_severe_vs_COVID19_negative_or_unknown	T	1.096[1.022,1.175]	1.01E-02	1174 852 158	384940 259919 44761	0.253	2184	689620	1.09[0.998,1.191]	1.19[1.007,1.407]	0.4745
ABO	rs9411378)		COVID19_positive_vs_COVID19_negative	T	1.097[1.078,1.117]	9.96E-24	28215 20747 3668	61047 41288 7270	0.259	52630	109605	1.114[1.089,1.14]	1.136[1.088,1.187]	0.6010
			COVID19_positive_vs_COVID19_negative_or_unknown	T	1.098[1.081,1.114]	7.07E-34	28215 20747 3668	393656 264837 45523	0.254	52630	704016	1.109[1.088,1.13]	1.165[1.123,1.209]	0.1825
			COVID19_positive_hospitalized_vs_COVID19_negative_or_unknown	G	0.968[0.934,1.003]	7.67E-02	2988 3067 856	283922 316030 89668	0.359	6911	689620	0.945[0.898,0.994]	0.949[0.879,1.025]	0.6392
2 24 12			COVID19 positive_not_hospitalized_vs_COVID19_negative_or_unknown	G	0.997[0.983,1.012]	7.18E-01	19607 20340 5694	290868 322016 91132	0.358	45641	704016	0.976[0.956,0.997]	0.992[0.961,1.024]	0.4075
12q24.13 OAS3	rs10735079	12:112942203:G:A	COVID19_positive_severe_vs_COVID19_negative_or_unknown	G	0.975[0.915,1.039]	4.31E-01	942 973 269	283922 316030 89668	0.359	2184	689620	0.953[0.87,1.043]	0.957[0.835,1.097]	0.9016
UAS3			COVID19_positive_vs_COVID19_negative	G	0.996[0.979,1.012]	6.09E-01	22636 23437 6557	45628 49969 14008	0.353	52630	109605	0.97[0.948,0.993]	0.987[0.953,1.022]	0.7406
			COVID19 positive vs COVID19 negative or unknown	G	0.993[0.979,1.007]	3.11E-01	22636 23437 6557	290868 322016 91132	0.357	52630	704016	0.972[0.953,0.991]	0.986[0.958,1.016]	0.3908
			COVID19_positive_hospitalized_vs_COVID19_negative_or_unknown	A	1.100[1.061,1.141]	3.44E-07	3180 2954 777	327458 294675 67487	0.312	6911	689620	1.055[1.003,1.11]	1.227[1.134,1.328]	0.0945
			COVID19 positive not hospitalized vs COVID19 negative or unknown	A	1.007[0.992,1.023]	3.59E-01	22268 19042 4331	335629 299944 68443	0.310	45641	704016	0.994[0.973,1.015]	1.027[0.992,1.064]	0.1766
19p13.3	rs2109069	19:4719431:G:A	COVID19 positive severe vs COVID19 negative or unknown	A	1.121[1.050,1.196]	5.93E-04	994 936 254	327458 294675 67487	0.312	2184	689620	1.073[0.981,1.173]	1.308[1.139,1.502]	0.8598
DPP9			COVID19_positive_vs_COVID19_negative	A	1.017[0.999,1.034]	6.21E-02	25489 22028 5113	53011 46169 10425	0.306	52630	109605	1.012[0.989,1.035]	1.051[1.012,1.092]	0.5871
			COVID19 positive vs COVID19 negative or unknown	A	1.019[1.004,1.034]	1.02E-02	25489 22028 5113	335629 299944 68443	0.310	52630	704016	1.003[0.984,1.022]	1.054[1.021,1.089]	0.5211
			COVID19_positive_hospitalized_vs_COVID19_negative_or_unknown	A	1.092[1.011,1.180]	2.59E-02	6201 681 29	620702 67104 1814	0.051	6911	689620	1.052[0.971,1.139]	1.668[1.155,2.41]	0.0060
			COVID19 positive not hospitalized vs COVID19 negative or unknown	A	1.012[0.978,1.046]	4.97E-01	41354 4180 107	634281 67914 1821	0.051	45641	704016	1.007[0.973,1.042]	0.959[0.784,1.174]	0.3301
19p13.2	rs74956615	19:10317045:T:A	COVID19_positive_severe_vs_COVID19_negative_or_unknown	A	1.244[1.087,1.424]	1.58E-03	1937 238 9	620702 67104 1814	0.051	2184	689620	1.188[1.037,1.36]	1.672[0.867,3.225]	0.1839
RAVER1			COVID19 positive vs COVID19 negative	A	1.022[0.984,1.060]	2.60E-01	47425 4863 136	98596 10384 282	0.050	52424	109262	1.008[0.972,1.046]	1.068[0.865,1.319]	0.9762
			COVID19 positive vs COVID19 negative or unknown	A	1.022[0.991,1.055]	1.64E-01	47630 4864 136	634281 67914 1821	0.051	52630	704016	1.012[0.98,1.044]	1.061[0.886,1.27]	0.3694
			COVID19 positive hospitalized vs COVID19 negative or unknown	A	1.079[1.039,1.120]	7.34E-05	3369 2898 644	351679 280661 57280	0.287	6911	689620	1.079[1.026,1.134]	1.165[1.07,1.269]	0.4116
21 22 1			COVID19_positive_not_hospitalized_vs_COVID19_negative_or_unknown	A	1.012[0.996,1.028]	1.51E-01	22463 18988 4190	358003 286693 59320	0.289	45641	704016	1.021[1,1.042]	1.031[0.995, 1.069]	0.2857
21q22.1	rs2236757	21:33252612:A:G	COVID19 positive severe vs COVID19 negative or unknown	A	1.140[1.066,1.218]	1.10E-04	1032 930 222	351679 280661 57280	0.287	2184	689620	1.125[1.029,1.23]	1.295[1.118,1.5]	0.3644
IFNAR2			COVID19 positive vs COVID19 negative	A	1.026[1.009,1.045]	3.50E-03	25861 21920 4849	55434 44836 9335	0.293	52630	109605	1.029[1.005,1.052]	1.054[1.013,1.096]	0.8180
			COVID19 positive vs COVID19 negative or unknown	A	1.023[1.008,1.038]	2.51E-03	25861 21920 4849	358003 286693 59320	0.289	52630	704016	1.028[1.008,1.048]	1.048[1.014,1.083]	0.6665

Supplementary Table 13. Comparison of effect sizes between ancestries for the six published risk variants that were validated in this study.

Locus, nearest gene	rs ID	hg38	Effect allele	Phenotype	Ancestry	Odds Ratio (95% CI)	P-value	N cases with 0 1 2 copies of the effect allele	N controls with 0 1 2 copies of the effect allele	Effect allele frequency	Cross-ancestry heterogeneity test P-value
					AFR	0.9 (0.84, 0.98)	0.0091	716 1353 657	1200 2672 1327	0.504	
3p21.31					AMR	0.91 (0.85, 0.98)	0.0155	1606 1778 456	1457 1727 525	0.362	
SLC6A20	rs2531743	3:45796808:G:A	G	COVID19 positive vs COVID19 negative	EAS	0.96 (0.6, 1.54)	0.8615	142 60 4	228 101 14	0.179	0.647
SEC01120					EUR	0.95 (0.93, 0.96)	8.41E-10	15747 21938 7338	33271 48507 17392	0.416	
					SAS	0.94 (0.79, 1.12)	0.498	381 380 74	504 551 129	0.331	
					AFR	1.11 (0.42, 2.95)	0.8284	126 3 1	22413 641 2	0.014	
3p21.31	rs73064425	3:45859597:C:T	T	COVID19 positive severe vs COVID19 negative or unknown	AMR	1.63 (0.81, 3.27)	0.1731	69 11 1	11052 1236 35	0.053	0.577
LZTFL1	1373001123	3.13037377.C.1		COVIDITY positive severe vs COVIDITY negative of unknown	EUR	1.6 (1.44, 1.78)	4.32E-18	1522 391 28	553956 86912 3491	0.073	0.577
					SAS	1.26 (0.68, 2.31)	0.4591	15 16 1	5550 3667 665	0.253	
					AFR	1.0 (0.86, 1.17)	0.9888	2412 307 7	4640 542 17	0.057	
6p21.33					AMR	1.02 (0.92, 1.14)	0.6816	2937 846 57	2904 747 58	0.121	
CCHCR1	rs143334143	6:31153649:G:A	A	COVID19 positive vs COVID19 negative	EAS	0.8 (0.44, 1.44)	0.4582	166 36 4	285 55 3	0.096	0.427
					EUR	1.06 (1.03, 1.1)	0.0001	38029 6686 308	84722 13856 592	0.077	
					SAS	1.09 (0.87, 1.35)	0.4527	654 165 16	944 227 13	0.111	
					AFR	1.1 (1.01, 1.2)	0.0224	1781 858 87	18064 7277 765	0.171	
9q34.2	rs879055593				AMR	1.16 (1.08, 1.24)	2.42E-05	2391 1272 177	8706 4386 538	0.203	
ABO	(proxy for	9:133271182:T:C	T	COVID19 positive vs COVID19 negative or unknown	EAS	1.23 (0.93, 1.64)	0.1535	123 75 8	1815 851 113	0.196	0.183
1120	rs9411378)				EUR	1.1 (1.08, 1.11)	7.89E-30	23347 18306 3370	358276 249302 43780	0.260	
					SAS	0.95 (0.83, 1.1)	0.491	573 236 26	6795 3021 327	0.180	
					AFR	1.32 (1.11, 1.56)	0.0014	229 155 31	14025 7882 1149	0.221	
19p13.3	rs2109069	19:4719431:G:A		COVID19 positive hospitalized vs COVID19 negative or unknown	AMR	0.94 (0.74, 1.2)	0.6154	116 72 11	6722 4760 841	0.261	0.094
DPP9	rs2109069	19:4/19431:G:A	A	COVID19 positive nospitalized vs COVID19 negative or unknown	EUR	1.09 (1.05, 1.14)	4.87E-06	2743 2672 726	300516 278789 65054	0.317	0.094
					SAS	1.15 (0.85, 1.56)	0.3533	92 55 9	6195 3244 443	0.209	
					AFR	1.05 (0.88, 1.25)	0.5825	245 145 25	13867 7992 1197	0.225	
21q22.1		21-22252612-4-6		COVID10iti 1it-1i1 COVID10ti	AMR	1.25 (1.02, 1.53)	0.0355	55 111 33	4813 5759 1751	0.377	0.412
IFNAR2	^ rs22366/57 21:33252612:Δ·G Δ LCO	COVIDIA positive pospitalized as COVIDIA negative or linknown	EUR	1.08 (1.03, 1.12)	0.0003	3011 2578 552	329458 262225 52676	0.285	0.412		
					SAS	1.03 (0.81, 1.32)	0.7863	58 64 34	3541 4685 1656	0.405	

Supplementary Table 14. Association between two severity phenotypes and six published risk variants for COVID-19 that validated in this study.

Locus, nearest gene	rs ID	hg38	Phenotype	Effect allele	Odds Ratio* [95% CI]	P-value	N cases with 0 1 2 copies of the effect allele	N controls with 0112		N cases	N controls	Heterozygote Odds Ratio** [95% CI]	Homozygote Odds Ratio** [95% CI]	Cross-study heterogeneity test P-value
3p21.31	rs2531743	3:45796808:G:A	COVID19_positive_hospitalized_vs_COVID19_positive_not_hospitalized_combined	G	1.023[0.980,1.068]	2.99E-01	2398 3345 1168	15913 21963 7309	0.406	6911	45185	1.016[0.958,1.078]	1.038[0.959,1.124]	0.1999
SLC6A20	182331743	3.43/90808.G.A	COVID19_positive_severe_vs_COVID19_positive_not_hospitalized_combined	G	0.949[0.884,1.019]	1.47E-01	776 1072 336	15913 21963 7309	0.405	2184	45185	1.000[0.909,1.1]	0.92[0.806, 1.051]	0.5371
3p21.31	rs73064425	3:45859597:C:T	COVID19_positive_hospitalized_vs_COVID19_positive_not_hospitalized_combined	T	1.338[1.243,1.442]	1.50E-14	5713 1127 71	38671 6256 258	0.077	6911	45185	1.269[1.18,1.365]	1.835[1.393,2.418]	0.0522
LZTFL1	IS/3004423	3:43839397:C:1	COVID19_positive_severe_vs_COVID19_positive_not_hospitalized_combined	T	1.591[1.417,1.786]	4.28E-15	1732 421 31	38671 6256 258	0.077	2184	45185	1.545[1.381,1.728]	2.81[1.916,4.121]	0.5010
6p21.33	rs143334143	6:31153649:G:A	COVID19_positive_hospitalized_vs_COVID19_positive_not_hospitalized_combined	A	1.097[1.018,1.182]	1.54E-02	5839 1017 55	37929 6929 327	0.084	6911	45185	1.055[0.98,1.137]	1.363[1.011,1.836]	0.2440
CCHCR1	18143334143	0:31133049:G:A	COVID19_positive_severe_vs_COVID19_positive_not_hospitalized_combined	A	1.142[1.013,1.289]	3.06E-02	1814 347 23	37929 6929 327	0.084	2184	45185	1.115[0.99,1.255]	1.71[1.111,2.631]	0.6952
9q34.2	rs879055593 (proxy	9:133271182:T:C	COVID19 positive hospitalized vs COVID19 positive not hospitalized combined	T	1.022[0.976,1.071]	3.56E-01	3743 2658 510	24131 17915 3139	0.268	6911	45185	0.972[0.919,1.028]	1.049[0.945,1.165]	0.9457
ABO	for rs9411378)	9.1332/1162.1.C	COVID19_positive_severe_vs_COVID19_positive_not_hospitalized_combined	T	1.000[0.926,1.080]	9.98E-01	1174 852 158	24131 17915 3139	0.268	2184	45185	0.979[0.894,1.073]	1.023[0.861,1.216]	0.4760
19p13.3	rs2109069	19:4719431:G:A	COVID19_positive_hospitalized_vs_COVID19_positive_not_hospitalized_combined	A	1.081[1.034,1.129]	5.66E-04	3180 2954 777	21966 18903 4316	0.308	6911	45185	1.067[1.008,1.128]	1.223[1.119,1.337]	0.0077
DPP9	182109009	19.4/19431.G.A	COVID19_positive_severe_vs_COVID19_positive_not_hospitalized_combined	A	1.097[1.021,1.180]	1.20E-02	994 936 254	21966 18903 4316	0.306	2184	45185	1.082[0.986,1.186]	1.281[1.111,1.479]	0.4921
21q22.1	rs2236757	21:33252612:A:G	COVID19_positive_hospitalized_vs_COVID19_positive_not_hospitalized_combined	A	1.075[1.027,1.124]	1.76E-03	3369 2898 644	22305 18785 4095	0.299	6911	45185	1.064[1.006,1.125]	1.137[1.033,1.251]	0.6332
IFNAR2	182230737	21:33232612:A:G	COVID19_positive_severe_vs_COVID19_positive_not_hospitalized_combined	A	1.101[1.022,1.185]	1.09E-02	1032 930 222	22305 18785 4095	0.299	2184	45185	1.102[1.006,1.208]	1.257[1.081,1.463]	0.3129
* Estimated ba	* Estimated based on trans-ancestry inverse-variance meta-analysis across UKB, AncestryDNA, GHS and UPENN-PMBB.													
** Estimated b	ased on ancestry-specific	genotype counts in UKB,	AncestryDNA, GHS and UPENN-PMBB, using the Mantel-Haenszel procedure.											

Supplementary Table 15. Fifteen variants associated with COVID-19 in the latest meta-analyses performed by the COVID-19 Host Genetics Initiative*.

							·		HGI phenotype		ssociation with	risk of hospitaliza	tion among cases in	our study			Association wi	th risk of severe	disease among cases	in our study	
Locus index	rs ID	hg38	Nearest gene	HGI phenotype	Effect allele	Odds Ratio	P-value		independent from disease severity phenotypes among cases		P-value	N cases RR RA AA	N controls RR RA AA	AAF	Cross-study heterogeneity test P-value	Odds Ratio (95% CI)	P-value	N cases RR RA AA	N controls RR RA AA	AAF	Cross-study heterogeneity test P-value
1	rs10490770	3:45823240:T:C	LZTFL1		C	1.16	9.72E-30	Yes	Yes												
2	rs912805253	9:133274084:C:T	ABO	C2 - Reported infection	T	0.9	1.45E-39	Yes	Yes												
3	rs10774671	12:112919388:G:A	OAS1	C2 - Reported Injection	A	1.06	1.61E-11	Yes	Yes			Variante in four losi	that ware reported in	nomious GV	VAS Accordation buts	veen these loci and disea	sa caranity ic in	oluded in Supple	mantan: Tabla 10		
4	rs2109069	19:4719431:G:A	DPP9		A	1.05	4.08E-09	Yes	Yes			variants in four foci	mar were reported in	picvious GV	VAS. Association ber	veen these foer and disca	ise severity is in	iciaaca iii Sappic	memary rapic ro.		
5	rs74956615	19:10317045:T:A	RAVERI	B2 - Risk of hospitalization	T	1.27	5.05E-10	Yes	No												
6	rs13050728	21:33242905:T:C	IFNAR2	B2 - Risk of nospituitzation	C	0.86	2.72E-20	Yes	No												
7	rs67579710	1:155203736:G:A	THBS3		A	0.87	3.38E-08	No	No												
8	rs1381109	2:166061783:G:T	SCNIA	B2 - Risk of hospitalization	T	0.91	4.21E-08	No	No	Voidanto in Consumo to	.: 4:4 :	sh- HCI	· · · · · · · · · · · · · · · · · · ·	22) 45-4		two disease severity phe					
9	rs72711165	8:124324323:T:C	TMEM65	B2 - Risk of nospitalization	C	1.37	2.13E-09	No	No	variants in five new loc	a discovered in	the rior analysis or	menotypes (A2 and r	(a) that are n	disease severity		notypes tested i	n our study. As s	ucii, we did not test ii	tnese variants	were associated with
10	rs1819040	17:46142465:T:A	KANSLI		A	0.88	1.83E-10	No	No						disease severity	among casess.					
11	rs77534576	17:49863303:C:T	TAC4	A2 - rusk of severe disease	T	1.45	4.37E-09	No	No												
12	rs11919389	3:101705614:T:C	RPL24		C	0.94	3.40E-15	No	Yes	0.962[0.921,1.005]	0.084	3142 3025 744	20405 19847 4933	0.328	0.751	0.923[0.859,0.992]	0.029	1015 961 208	20405 19847 4933	0.328	0.767
13	rs10070196	5:13939721:A:C	DNAH5	C2 - Reported infection	C	1.05	2.30E-08	No	Yes	0.989[0.947,1.033]	0.622	793 3038 3080	5100 19947 20138	0.666	0.451	0.956[0.890,1.027]	0.218	242 1017 925	5100 19947 20138	0.666	0.739
14	rs1886814	6:41534945:A:C	FOXP4	C2 - Reported Injection	C	1.11	2.40E-08	No	Yes	1.159[1.031,1.302]	0.013	6435 458 18	41747 3252 186	0.040	0.126	1.255[1.039,1.517]	0.018	2024 152 8	41747 3252 186	0.040	0.445
15	rs4801778	19:48867352:G:T	PLEKHA4		T	0.95	1.20E-08	No	Yes	$Y_{\text{CS}} = 0.999[0.946, 1.055] = 0.966 - 4670[2028]213 - 30955[12887]1343 - 0.173 - 0.165 - 0.925[0.845, 1.012] - 0.090 - 1513[60962 - 30955[12887]1343 - 0.172 - 0.919$									0.919		

^{*} Reported in Table 1 of https://www.medrxiv.org/content/10.1101/2021.03.10.21252820v1. If a variant was associated with multiple phenotypes, we show results for C2 over B2 over A2.

Supplementary Table 16. Missense or predicted loss-of-function variants in high linkage disequilibrium (LD, r2>0.80) with sentinel GWAS variants.

	Se	entinel GWAS varia	int		Missense	e or pLOF in high Ll	D with lead variant		
Locus	rs ID	hg38	Nearest gene	Gene	rs ID	hg38	r2 with sentinel GWAS variant*	Variant effect	
21,222,1	rs2236757	21,22252612, A.C	IFNAR2	IFNAR2	rs1051393	21:33241950:T:G	0.88	Missense:Phe10Val	
21q22.1	182230737	57 21:33252612:A:G <i>IFN</i> .		IFNAK2	rs1131668	21:33262573:G:A	0.86	Missense:Ala285Thr	
					rs130072	6:31144707:C:T	1.00	Missense:Arg716Gln	
				CCHCR1	rs11540822	6:31151121:A:T	1.00	Missense:Leu268Gln	
6-21-22	rs143334143	6:31153649:G:A	CCHCDI		rs72856718	6:31157480:C:A	1.00	Stop_gained:Glu41X	
6p21.33	18145554145	0:31133049:G:A	CCHCRI	CCHCRI	TCF19	rs2073724	6:31161930:C:T	1.00	Missense:Pro241Leu
					C6orf15	rs2233976	6:31112217:C:T	0.87	Missense:Gly48Arg
				PSORS1C1	rs1265097	6:31138682:C:A	0.84	Missense:Pro24Thr	
* LD estima	ated based on inc	dividuals of Europea	n ancestry from t	the 1000 Genomes	project				

Supplementary Table 17. Expression quantitative trait loci (eQTL) that co-localized (LD r2>0.80) with sentinel GWAS variants.

Part							Sentinel eQTL		<u> </u>	()		GWAS variant		- Сересс
1190389 3.1079564ETC T 8.1500290 3.10715918-GA N.PE3 GTEVS Eorphage Miscularis 3.277-40 A G 0.753 0.99	inel with disease predisposing allele	sentinel GWAS variant*		allele	allele				Ü		predisposing allele	J		
18915189 3:101785614TC T 0:13100262 3:101695258TC NNPB Total State Sta														3p21.31
1992 1993 1997													rs11919389	
mi199389 330078564FTC T														
m19191988 3.101705648-FC T											_		rs11919389	3p21.31
mi4334448													rs11919389	
m14334413											T		rs11919389	
np											A	6:31153649:G:A	rs143334143	
Fig. 1333443 6:31153649:GA A Fil270190 6:3115370:CT TCF19 GTeVs Artery Aoria 2.14E-22 T C 1.019 0.998							-				A			
No. No.											A		rs143334143	
Part					T		_ ·-				A		rs143334143	
Page													rs143334143	
First Firs							_ 1 _				A		rs143334143	
R143344143 G-31153649-G-A A R17197087 G-31158455-C:T TCF19 Ratanapyia Retina 4.25E-30 T C 1.371 0.976 1.43334413 G-31153649-G-A A R17197087 G-31158455-C:T TCF19 GTEXV8 Brain Grottex 3.28E-22 T C 1.142 0.976 G-31158455-C:T TCF19 GTEXV8 Brain Grottex 3.28E-22 T C 1.142 0.976 G-31158455-C:T TCF19 GTEXV8 Brain Grottex G-315649-G-A A R17197087 G-31158455-C:T TCF19 GTEXV8 Brain Hypothalamus R.32E-17 T C 1.383 0.976 R143334143 G-31153649-G-A A R17197087 G-31158455-C:T TCF19 GTEXV8 Brain Grottex G-3164-1 T C 0.474 0.976 R143334143 G-31153649-G-A A R17197087 G-31158455-C:T TCF19 GTEXV8 Brain Grottex G-3164-1 T C 0.976 R143334143 G-31153649-G-A A R17197087 G-31158455-C:T TCF19 GTEXV8 Brain Grottex G-316-14 T C 0.976 R143334143 G-31153649-G-A A R17197087 G-31158455-C:T TCF19 GTEXV8 Brain Grottex G-316-14 T C 0.976 R143334143 G-31153649-G-A A R17197101 G-31158632-G:T TCF19 GTEXV8 Brain Grottex G-316-14 T C 0.976 R143334143 G-31153649-G-A A R17197101 G-31158632-G:T TCF19 GTEXV8 Brain Grottex G-316-14 T C 0.976 R143334143 G-31153649-G-A A R17197101 G-31158632-G:T TCF19 Bratte Whole Blood 3.48E-99 NA NA 0 0.975 R143334143 G-31153649-G-A A R17197101 G-31158632-G:T TCF19 Bratte Whole Blood 3.48E-99 NA NA 0 0.975 R143334143 G-31153649-G-A A R17197101 G-31158632-G:T TCF19 R1498-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M-M							GTeXv8Whole_Blood	TCF19	6:31221764:G:A	rs72863830	A	6:31153649:G:A	rs143334143	
First														
First Firs		0.976	-0.091		C	1.61E-98		TCF19	6:31158455:C:T	rs17197087	A	6:31153649:G:A	rs143334143	
6p21.33 s143334143 6:31153649:G:A A s17197087 6:31158455:C:T TCF19 GTCXV8 Pituitary 4.58E-22 T C 1.108 0.976 s143334143 6:31153649:G:A A s17197087 6:31158455:C:T TCF19 GTcXV8 Brain Crebellar Henrisphere 1.95E-17 T C 1.215 0.976 s143334143 6:31153649:G:A A s17197087 6:31158455:C:T TCF19 GTcXV8 Brain Crebellar Henrisphere 1.95E-17 T C 1.215 0.976 s143334143 6:31153649:G:A A s17197087 6:31158455:C:T TCF19 GTcXV8 Brain Hypothalamus 8.32E-17 T C 1.383 0.976 s143334143 6:31153649:G:A A s17197087 6:31158455:C:T TCF19 GTcXV8 Brain Hypothalamus 8.32E-17 T C 0.474 0.976 ms143334143 6:31153649:G:A A s17197087 6:31158455:C:T TCF19 GTcXV8 Brain Caudate basal ganglia 4:73E-10 T C 0.956 0.976 ms143334143 6:31153649:G:A A s17197087 6:31158455:C:T TCF19 GTcXV8 Brain Frontal Cortex BAP 6:58E-10 T C 0.961 0.976 ms143334143 6:31153649:G:A A s17197087 6:31158455:C:T TCF19 GTcXV8 Brain Frontal Cortex BAP 6:58E-10 T C 0.961 0.976 ms143334143 6:31153649:G:A A s17197101 6:3115862:G:T TCF19 GTcXV8 Brain Amysdala 1.14E-09 T C 1.241 0.976 ms143334143 6:31153649:G:A A s17197101 6:3115862:G:T TCF19 GTcXV8 Brain Prontal Cortex BAP Max Max	76 T	0.976	1.371		T		RatnapryiaRetina	TCF19	6:31158455:C:T	rs17197087	A	6:31153649:G:A	rs143334143	
February February							GTeXv8_Brain_Cortex				A	6:31153649:G:A	rs143334143	
Bi43334143 6:31153649-G:A A Bi7197087 6:31158455-C:T TCF19 Chen CD4Tcells 1.35E-18 T C 1.82 0.976	76 T	0.976	1.108		T	4.58E-22	GTeXv8Pituitary	TCF19	6:31158455:C:T	rs17197087	A	6:31153649:G:A	rs143334143	6n21 33
B14333443 6.31153649-G:A A B17197087 6.31158455-C:T TCF19 GTEXV8 Brain Hypothalamus B.32E-17 T C 1.383 0.976 B14333443 6.31153649-G:A A B17197087 6.31158455-C:T TCF19 GTEXV8 Brain Caudate basal ganglia 4.73E-10 T C 0.474 0.976 B14333443 6.31153649-G:A A B17197087 6.31158455-C:T TCF19 GTEXV8 Brain Caudate basal ganglia 4.73E-10 T C 0.976 B14333443 6.31153649-G:A A B17197087 6.31158455-C:T TCF19 GTEXV8 Brain Frontal Cortex BA9 6.53E-10 T C 0.961 0.976 B14333443 6.31153649-G:A A B17197087 6.31158455-C:T TCF19 GTEXV8 Brain Amygdala 1.14E-09 T C 1.241 0.976 B14333443 6.31153649-G:A A B17197101 6.31158632-G:T TCF19 Battle Whole Blood 3.43E-99 NA NA 0 0.975 B14333443 6.31153649-G:A A B17197101 6.31158632-G:T TCF19 Battle Whole Blood 3.43E-99 MA NA 0 0.975 B14333443 6.31153649-G:A A B17197101 6.31158632-G:T TCF19 Davemport Whole Blood 1.50E-36 T G 0.438 0.975 B14333443 6.31153649-G:A A B17197101 6.31158632-G:T TCF19 Davemport Whole Blood 2.54E-15 NA NA 0 0.975 B14333443 6.31153649-G:A A B17197101 6.31158632-G:T TCF19 Battle Whole Blood 2.54E-15 NA NA 0 0.975 B14333443 6.31153649-G:A A B17197101 6.31158632-G:T TCF19 Battle Whole Blood 2.54E-15 NA NA 0 0.975 B14333443 6.31153649-G:A A B123325612-A:G A B12332561	76 T	0.976	1.82	C	T	1.35E-18	ChenCD4Tcells	TCF19	6:31158455:C:T	rs17197087	A	6:31153649:G:A	rs143334143	op21.55
Side		0.976				1.95E-17	GTeXv8_Brain_Cerebellar_Hemisphere	TCF19	6:31158455:C:T	rs17197087	A	6:31153649:G:A	rs143334143	
Fil43334143 6:31153649:G:A A Fil7197087 6:31158455:C:T TCF19 GTeXv8 Brain Caudate basal ganglia 4.73E-10 T C 1.02 0.976	76 T	0.976	1.383	C	T	8.32E-17	GTeXv8Brain_Hypothalamus	TCF19	6:31158455:C:T	rs17197087	A	6:31153649:G:A	rs143334143	
International Content Inte	76 T	0.976	0.474	C	T	6.93E-14	GTeXv8Muscle_Skeletal	TCF19	6:31158455:C:T	rs17197087	A	6:31153649:G:A	rs143334143	
B143334143 G:31153649:G:A A B:17197087 G:31158455:C:T TCF19 GTeXv8 Brain Amygdala D:14E-09 T C D:241 D:976 B:43334143 G:31153649:G:A A B:17197101 G:31158632:G:T TCF19 Battle Whole Blood D:45E-49 Research R	76 T	0.976	1.02	C	T	4.73E-10	GTeXv8Brain_Caudate_basal_ganglia	TCF19	6:31158455:C:T	rs17197087	A	6:31153649:G:A	rs143334143	
Fil43334143 6:31153649:G:A A Fil7197101 6:31158632:G:T TCF19 Battle_Whole_Blood 3.43E-99 NA NA 0 0.975	76 T	0.976	0.961	C	T	6.53E-10	GTeXv8_Brain_Frontal_Cortex_BA9	TCF19	6:31158455:C:T	rs17197087	A	6:31153649:G:A	rs143334143	
Fish	76 T	0.976	1.241	C	T	1.14E-09	GTeXv8Brain_Amygdala	TCF19	6:31158455:C:T	rs17197087	A	6:31153649:G:A	rs143334143	
Fis14334143 G:31153649:G:A A Fis17197101 G:31158632:G:T TCF19 Davenport Whole Blood Davenport Davenport Whole Blood Davenport Da	75 T	0.975	0	NA	NA	3.43E-99	BattleWhole_Blood	TCF19	6:31158632:G:T	rs17197101	A	6:31153649:G:A	rs143334143	
Fil4334143 6:31153649;G:A A Fil7197101 6:31158632;G:T TCF19 Walsh Whole Blood 2.54E-15 NA NA O 0.975 Fil43334143 6:31153649;G:A A Fil223376 6:31112217;C:T TCF19 Raj CD4Tcells 2.02E-27 NA NA O 0.872 Fil43334143 6:31153649;G:A A Fil43334143 CD4Tcells 2.02E-27 NA NA O 0.872 Fil43334143 6:31153649;G:A A Fil43334143 CD4Tcells 2.02E-27 NA NA O 0.872 Fil43334143 CD4Tcells 2.02E-27 NA NA O 0.872 Fil43334143 CD4Tcells 2.02E-27 NA NA O 0.872 Fil43334143 CD4Tcells CD4Tcells	75 T	0.975	-1.648	T	G	2.95E-49	Pala_Leucocytes	TCF19	6:31158632:G:T	rs17197101	A	6:31153649:G:A	rs143334143	
F314334143 6:31153649:G:A A F32233976 6:31112217:C:T TCF19 Raj CD4Tcells 2.02E-27 NA NA 0 0.872	75 T	0.975	0.438	G	T	1.50E-36	DavenportWhole_Blood	TCF19	6:31158632:G:T	rs17197101	A	6:31153649:G:A	rs143334143	
F8236757 21:33252612:A:G A F83153 21:33237200:G:A IFNAR2 Westra Whole Blood 1.97E-71 A G 17.871 0.997	75 T	0.975	0	NA	NA	2.54E-15	WalshWhole_Blood	TCF19	6:31158632:G:T	rs17197101	A	6:31153649:G:A	rs143334143	
Fis236757 21:33252612:A:G A Fis74424283 21:33232654:T:TAA IL10RB Brown LCLs 5.24E-11 NA NA 0 0.997	72 T	0.872	0	NA	NA	2.02E-27	RajCD4Tcells	TCF19	6:31112217:C:T	rs2233976	A	6:31153649:G:A	rs143334143	
Fis236757 21:33252612:A:G A Fis12053666 21:33246134:G:A IL10RB Kasela CD4Tcells 4.07E-13 A G 7.253 0.995	97 A	0.997	17.871	G	A	1.97E-71	WestraWhole_Blood	IFNAR2	21:33237200:G:A	rs3153	A	21:33252612:A:G	rs2236757	
Fis2236757 21:33252612:A:G A Fis2834163 21:33248146:G:A IFNAR2 GTEXV8 Muscle Skeletal 1.01E-15 A G -0.239 0.883	97 TAA	0.997	0	NA	NA	5.24E-11	BrownLCLs	IL10RB	21:33232654:T:TAA	rs574424283	A	21:33252612:A:G	rs2236757	
Fis2236757 21:33252612:A:G A Fis252639 21:33245424:A:G IFNAR2 LloydJones Whole Blood 4.60E-44 A G 0.411 0.88	95 A	0.995	7.253	G	A	4.07E-13	KaselaCD4Tcells	IL10RB	21:33246134:G:A	rs12053666	A	21:33252612:A:G	rs2236757	
rs2236757 21:33252612:A:G A rs17860115 21:33230000:C:A IFNAR2 Huang_LCLs 1.85E-24 C NA 0.483 0.88 rs2236757 21:33252612:A:G A rs17860115 21:33230000:C:A IFNAR2 Fairfax_Monocytes_naive 1.84E-20 NA NA 0 0.88 rs2236757 21:33252612:A:G A rs17860115 21:33230000:C:A IFNAR2 Huang_PBMCs 5.92E-20 C NA 0.678 0.88 rs2236757 21:33252612:A:G A rs17860115 21:33230000:C:A IFNAR2 Hao_Lung 1.00E-16 C A 11 0.88 rs2236757 21:33252612:A:G A rs2834158 21:33244908:T:C IFNAR2 Fairfax_Monocytes_IFN 2.22E-13 NA NA O 0.88	83 G	0.883	-0.239	G	A	1.01E-15	GTeXv8Muscle_Skeletal	IFNAR2	21:33248146:G:A	rs2834163	A	21:33252612:A:G	rs2236757	
rs2236757 21:33252612:A:G A rs17860115 21:33230000:C:A IFNAR2 Fairfax Monocytes naive 1.84E-20 NA NA 0 0.88 rs2236757 21:33252612:A:G A rs17860115 21:33230000:C:A IFNAR2 Huang PBMCs 5.92E-20 C NA 0.678 0.88 rs2236757 21:33252612:A:G A rs17860115 21:33230000:C:A IFNAR2 Hao_Lung 1.00E-16 C A 11 0.88 rs2236757 21:33252612:A:G A rs2834158 21:33244908:T:C IFNAR2 Fairfax Monocytes_IFN 2.22E-13 NA NA 0 0.88	88 A	0.88	0.411	G	A	4.60E-44	LloydJonesWhole_Blood	IFNAR2	21:33245424:A:G	rs2252639	A	21:33252612:A:G	rs2236757	
rs2236757 21:33252612:A:G A rs17860115 21:33230000:C:A IFNAR2 Huang_PBMCs 5.92E-20 C NA 0.678 0.88 rs2236757 21:33252612:A:G A rs17860115 21:33230000:C:A IFNAR2 Hao_Lung 1.00E-16 C A 11 0.88 rs2236757 21:33252612:A:G A rs2834158 21:33244908:T:C IFNAR2 Fairfax_Monocytes_IFN 2.22E-13 NA NA 0 0.88	88 A	0.88	0.483	NA	C	1.85E-24	HuangLCLs	IFNAR2	21:33230000:C:A	rs17860115	A	21:33252612:A:G	rs2236757	
rs2236757 21:33252612:A:G A rs17860115 21:33230000:C:A IFNAR2 Hao_Lung 1.00E-16 C A 11 0.88 rs2236757 21:33252612:A:G A rs2834158 21:33244908:T:C IFNAR2 Fairfax_Monocytes_IFN 2.22E-13 NA NA 0 0.88	88 A	0.88	0	NA	NA	1.84E-20	Fairfax_Monocytes_naive	IFNAR2	21:33230000:C:A	rs17860115	A	21:33252612:A:G	rs2236757	
rs2236757 21:33252612:A:G A rs2834158 21:33244908:T:C IFNAR2 Fairfax Monocytes IFN 2.22E-13 NA NA 0 0.88	88 A	0.88	0.678	NA	C	5.92E-20	HuangPBMCs	IFNAR2	21:33230000:C:A	rs17860115	A	21:33252612:A:G	rs2236757	
	88 A	0.88	11	A	С	1.00E-16	Hao_Lung	IFNAR2	21:33230000:C:A	rs17860115	A	21:33252612:A:G	rs2236757	
	88 T	0.88	0	NA	NA	2.22E-13	Fairfax Monocytes IFN	IFNAR2	21:33244908:T:C	rs2834158	A	21:33252612:A:G	rs2236757	
rs2236757 21:33252612:A:G A rs17860115 21:33230000:C:A IFNAR2 Momozawa_Monocytes 4.09E-11 A C -0.118 0.88	88 A	0.88	-0.118	С	A	4.09E-11	Momozawa_Monocytes	IFNAR2	21:33230000:C:A	rs17860115	A	21:33252612:A:G	rs2236757	
rs2236757 21:33252612:A:G A rs12482556 21:33230629:T:C IFNAR2 Momozawa_CD4Tcells 1.54E-16 C T -0.147 0.879	79 C	0.879	-0.147	T	С	1.54E-16	Momozawa_CD4Tcells	IFNAR2	21:33230629:T:C	rs12482556	A	21:33252612:A:G	rs2236757	
rs2236757 21:33252612:A:G A rs2236758 21:33253108:A:G IFNAR2 Battle Whole Blood splice 1.92E-147 NA NA 0 0.878														
rs2236757 21:33252612:A:G A rs2236758 21:33253108:A:G IFNAR2 Fehrmann Whole Blood 3.80E-19 A G 8.94 0.878 rs2236757 21:33252612:A:G A rs2250226 21:33260011:T:C IL10RB Westra Whole Blood 2.51E-13 C T 7.319 0.878														
21q22.1 rs2236757 21:33252612:A:G A rs2250226 21:33260011:T:C IL10RB Westra Whole Blood 2.51E-13 C T 7.319 0.878 rs2236757 21:33252612:A:G A rs17860241 21:33258828:A:G IFNAR2 Brown LCLs 1.17E-30 NA NA 0 0.876														21q22.1
132250737 21:33250121:A:G A 1517600241 21:33258828:A:G IFNAR2 GTEX/8 Adipose Subcutaneous 3.71E-18 G A -0.287 0.876				1										

	rs2236757	21:33252612:A:G	A	rs17860241	21:33258828:A:G	IFNAR2	GTeXv8 Esophagus Mucosa	1.49E-16	G	Α	-0.292	0.876	G
	rs2236757	21:33252612:A:G	A	rs11911133	21:33256870:A:G	IFNAR2	Vosa Whole Blood	2.09E-280	G	A	-35,782	0.875	G
	rs2236757	21:33252612:A:G	A	rs11911133	21:33256870:A:G	IFNAR2	Davenport Whole Blood	3.37E-16	G	A	-0.114	0.875	G
	rs2236757	21:33252612:A:G	A	rs9975538	21:33254549:C:T	IL10RB	GTeXv8 Muscle Skeletal	3.91E-13	T	С	-0.253	0.875	С
	rs2236757	21:33252612:A:G	A	rs6517156	21:33261740:C:G	IL10RB	Vosa_Whole_Blood	1.16E-117	G	С	23.06	0.862	G
	rs2236757	21:33252612:A:G	A	rs6517156	21:33261740:C:G	IL10RB	Joehanes Whole Blood	5.21E-41	C	G	-0.038	0.862	G
	rs2236757	21:33252612:A:G	A	rs6517156	21:33261740:C:G	IFNAR2	LappalainenLCLs	7.65E-36	NA	NA	0	0.862	G
	rs2236757	21:33252612:A:G	A	rs6517156	21:33261740:C:G	IL10RB	GTeXv8 Cells Cultured fibroblasts	1.82E-29	G	C	-0.264	0.862	G
	rs2236757	21:33252612:A:G	A	rs6517156	21:33261740:C:G	IFNAR2	Brown_Adipose	2.87E-25	NA	NA	0	0.862	G
	rs2236757	21:33252612:A:G	A	rs6517156	21:33261740:C:G	IL10RB	GTeXv8 Brain Cerebellum	4.75E-25	G	C	0.687	0.862	G
	rs2236757	21:33252612:A:G	A	rs6517156	21:33261740:C:G	IL10RB	GTeXv8 Brain Cerebellar Hemisphere	4.35E-17	G	C	0.586	0.862	G
	rs2236757	21:33252612:A:G	A	rs6517156	21:33261740:C:G	IL10RB	GTeXv8 Brain Cortex	2.64E-12	G	C	0.427	0.862	G
	rs2236757	21:33252612:A:G	A	rs1131668	21:33262573:G:A	IFNAR2	Walsh Whole Blood	1.60E-30	NA	NA	0	0.86	A
	rs2236757	21:33252612:A:G	A	rs1131668	21:33262573:G:A	IFNAR2	Alasoo Macrophages naive	1.14E-12	NA	NA	0	0.86	A
	rs2236757	21:33252612:A:G	A	rs1131668	21:33262573:G:A	IFNAR2	Alasoo Macrophages IFNg	3.25E-10	NA	NA	0	0.86	A
	rs2236757	21:33252612:A:G	A	rs3216172	21:33262748:G:GT	IL10RB	GTeXv8 Nerve Tibial	1.62E-14	GT	G	0.344	0.857	GT
* LD estima	ated based on individ	luals of European ancestry	from the 1000 (Genomes project									

Supplementary Table 18. Association between a 6-SNP genetic risk score (GRS) and risk of hospitalization among COVID-19 cases.

Population, total N COVID-19 cases	GRS Group	Risk of hospitalization	on among COVID-19 cases oitalized / N positive) x 100	Unadjusted Risk	•		sted Odds		
COVID-19 Cases		Highest GRS group	Rest of Population	Difference	Estimate	SE	LCI	UCI	P-value
		F							
	Top 40% vs Rest of population	7.33 (729/9947)	4.90 (755/15406)	2.43	1.54	0.06	1.38	1.72	6.7E-15
A A DNIA ELID	Top 30% vs Rest of population	7.40 (555/7501)	5.20 (929/17852)	2.20	1.46	0.06	1.31	1.64	4.2E-11
AncestryDNA EUR	Top 20% vs Rest of population	8.09 (407/5029)	5.30 (1077/20324)	2.79	1.59	0.06	1.40	1.80	2.5E-13
N=25,353	Top 10% vs Rest of population	9.04 (228/2522)	5.50 (1256/22831)	3.54	1.75	0.08	1.50	2.04	1.4E-12
	Top 5% vs Rest of population	9.73 (120/1233)	5.66 (1364/24120)	4.08	1.75	0.11	1.43	2.16	1.1E-07
	Top 40% vs Rest of population	16.23 (343/2114)	13.65 (433/3171)	2.57	1.23	0.09	1.03	1.48	0.024
CHC EHD	Top 30% vs Rest of population	16.77 (266/1586)	13.79 (510/3699)	2.98	1.25	0.10	1.03	1.51	0.024
GHS EUR	Top 20% vs Rest of population	18.07 (191/1057)	13.84 (585/4228)	4.23	1.32	0.11	1.07	1.64	0.011
N=5,285	Top 10% vs Rest of population	18.34 (97/529)	14.28 (679/4756)	4.06	1.28	0.15	0.96	1.70	0.091
	Top 5% vs Rest of population	18.87 (50/265)	14.46 (726/5020)	4.41	1.27	0.20	0.86	1.88	0.230
	Top 40% vs Rest of population	28.25 (1479/5235)	26.41 (2399/9085)	1.85	1.13	0.04	1.03	1.23	6.1E-03
UKB EUR	Top 30% vs Rest of population	28.37 (1214/4279)	26.53 (2664/10041)	1.84	1.13	0.05	1.03	1.23	0.011
N=14,320	Top 20% vs Rest of population	28.09 (795/2830)	26.83 (3083/11490)	1.26	1.06	0.05	0.96	1.18	0.255
N-14,520	Top 10% vs Rest of population	29.09 (398/1368)	26.87 (3480/12952)	2.23	1.17	0.07	1.01	1.34	0.032
	Top 5% vs Rest of population	30.53 (218/714)	26.90 (3660/13606)	3.63	1.24	0.10	1.03	1.49	0.024
	Top 40% vs Rest of population				1.27	0.03	1.19	1.35	2.3E-13
Meta-analysis EUR	Top 30% vs Rest of population				1.25	0.03	1.17	1.33	7.0E-11
N=44,958	Top 20% vs Rest of population				1.26	0.04	1.17	1.36	9.2E-10
11-44,936	Top 10% vs Rest of population				1.38	0.05	1.26	1.53	6.5E-11
	Top 5% vs Rest of population				1.43	0.07	1.25	1.63	1.0E-07
			African (AFR) ancestry						
	Top 40% vs Rest of population	8.9	7.88	1.01	1.33	0.23	0.84	2.09	0.220
AncestryDNA AFR	Top 30% vs Rest of population	8.59	8.16	0.43	1.18	0.25	0.73	1.91	0.499
N=1,629	Top 20% vs Rest of population	9.35	8.03	1.32	1.49	0.28	0.86	2.55	0.152
11-1,029	Top 10% vs Rest of population	6.88	8.44	-1.57	1.00	0.41	0.45	2.21	0.993
	Top 5% vs Rest of population	6.1	8.4	-2.31	0.73	0.58	0.23	2.28	0.587
	Top 40% vs Rest of population	28.63 (71/248)	20.70 (77/372)	7.93	1.62	0.24	1.00	2.60	0.048
UKB AFR	Top 30% vs Rest of population	27.57 (51/185)	22.30 (97/435)	5.27	1.37	0.26	0.83	2.27	0.220
N=620	Top 20% vs Rest of population	28.23 (35/124)	22.78 (113/496)	5.44	1.43	0.29	0.80	2.52	0.224
11-020	Top 10% vs Rest of population	37.70 (23/61)	22.36 (125/559)	15.34	2.61	0.37	1.25	5.42	0.010
	Top 5% vs Rest of population	41.94 (13/31)	22.92 (135/589)	19.02	3.12	0.52	1.13	8.58	0.028
	Top 40% vs Rest of population	45.00 (63/140)	33.01 (69/209)	11.99	1.92	0.41	1.20	5.88	0.016
PMBB AFR	Top 30% vs Rest of population	43.81 (46/105)	35.25 (86/244)	8.56	2.43	0.45	1.38	7.97	7.2E-03
N=349	Top 20% vs Rest of population	44.29 (31/70)	36.20 (101/279)	8.08	1.91	0.50	0.97	6.80	0.058
11 377	Top 10% vs Rest of population	42.86 (15/35)	37.26 (117/314)	5.60	1.73	0.72	0.57	9.58	0.241
	Top 5% vs Rest of population	50.00 (9/18)	37.16 (123/331)	12.84	2.30	1.01	0.48	25.16	0.219
	Top 40% vs Rest of population				1.52	0.15	1.12	2.05	0.007
Meta-analysis AFR	Top 30% vs Rest of population				1.39	0.17	1.00	1.93	5.1E-02
N=2 500	Top 20% vs Rest of population]			1.52	0.19	1.05	2.19	0.026

11-4,570	Top 10% vs Rest of population				1.70	0.26	1.03	2.81	0.038
	Top 5% vs Rest of population				1.71	0.36	0.84	3.47	0.140
		Admixed American	n (AMR) and South Asian (S	AS) ancestries					
	Top 40% vs Rest of population	5.89	4.91	0.98	1.16	0.16	0.85	1.60	0.343
AncestryDNA AMR	Top 30% vs Rest of population	6.9	4.63	2.27	1.41	0.16	1.02	1.95	0.037
N=3,752	Top 20% vs Rest of population	7.81	4.69	3.12	1.62	0.18	1.14	2.30	6.8E-03
N-3,732	Top 10% vs Rest of population	8.24	4.98	3.27	1.56	0.23	1.00	2.43	0.050
	Top 5% vs Rest of population	7.98	5.16	2.82	1.22	0.32	0.65	2.28	0.530
	Top 40% vs Rest of population	22.37 (68/304)	18.86 (86/456)	3.51	1.37	0.23	0.86	2.16	0.183
UKB SAS	Top 30% vs Rest of population	21.93 (50/228)	19.55 (104/532)	2.38	1.34	0.25	0.82	2.18	0.243
N=760	Top 20% vs Rest of population	23.84 (36/151)	19.38 (118/609)	4.47	1.37	0.28	0.80	2.35	0.256
IN-/00	Top 10% vs Rest of population	25.00 (19/76)	19.74 (135/684)	5.26	1.42	0.35	0.72	2.82	0.316
	Top 5% vs Rest of population	36.84 (14/38)	19.39 (140/722)	17.45	3.18	0.46	1.29	7.79	0.012

^{*} Logistic regression model adjusted for age, sex, age x sex, BMI, ancestry-informative PCs, REGENIE genome-wide predictor (to account for family structure) and clinical risk factors associated with risk of hospitalization and severe disease: chronic kidney disease, diabetes, immunosuppressive disease, chronic obstructive pulmonary disease or other chronic respiratory disease, cardiovascular disease, hyptertension (see methods for details)

Supplementary Table 19. Association between a 6-SNP genetic risk score (GRS) and risk of severe disease among COVID-19 cases.

Population, total N COVID-19 cases	GRS Group		among COVID-19 cases ere / N positive) x 100	Unadjusted Risk		Adjı	ısted Odds F	Ratio*				
COVID-19 Cases		Highest GRS group	Rest of Population	Difference	Estimate	SE	LCI	UCI	P-value			
			uropean (EUR) ancestry									
	Top 40% vs Rest of population	3.33 (331/9947)	2.18 (336/15406)	1.15	1.58	0.08	1.35	1.87	3.0E-08			
A DALL FUR	Top 30% vs Rest of population	3.60 (270/7501)	2.22 (397/17852)	1.38	1.69	0.08	1.43	1.99	7.9E-10			
AncestryDNA EUR	Top 20% vs Rest of population	3.96 (199/5029)	2.30 (468/20324)	1.65	1.74	0.09	1.45	2.08	1.5E-09			
N=25,353	Top 10% vs Rest of population	4.36 (110/2522)	2.44 (557/22831)	1.92	1.72	0.11	1.37	2.15	2.0E-06			
	Top 5% vs Rest of population	4.79	2.52	2.26	1.64	0.15	1.22	2.20	9.9E-04			
	Top 40% vs Rest of population	6.91 (146/2114)	5.55 (176/3171)	1.36	1.26	0.13	0.98	1.61	0.071			
CHC FIID	Top 30% vs Rest of population	7.19 (114/1586)	5.62 (208/3699)	1.56	1.27	0.13	0.98	1.64	0.074			
GHS EUR	Top 20% vs Rest of population	7.85 (83/1057)	5.65 (239/4228)	2.20	1.33	0.15	1.00	1.78	0.050			
N=5,285	Top 10% vs Rest of population	6.81 (36/529)	6.01 (286/4756)	0.79	1.03	0.20	0.69	1.53	0.877			
	Top 5% vs Rest of population	6.04 (16/265)	6.10 (306/5020)	-0.06	0.76	0.30	0.42	1.36	0.355			
	Top 40% vs Rest of population	7.98 (418/5235)	5.87 (533/9085)	2.12	1.43	0.07	1.24	1.66	1.4E-06			
THYD ELID	Top 30% vs Rest of population	2.49	1.49	0.08	1.28	1.73	2.5E-07					
UKB EUR	Top 20% vs Rest of population	8.73 (247/2830)	6.13 (704/11490)	2.60	1.44	0.09	1.21	1.70	2.5E-05			
N=14,320	Top 10% vs Rest of population	9.58 (131/1368)	6.33 (820/12952)	3.24	1.65	0.11	1.33	2.05	6.0E-06			
	Top 5% vs Rest of population	11.06 (79/714)	6.41 (872/13606)	4.66	2.00							
	Top 40% vs Rest of population		· · · · · · · · · · · · · · · · · · ·		1.46	0.05	1.32	1.61	1.3E-13			
Mata and and EID	Top 30% vs Rest of population				1.52	0.05	1.37	1.68	1.2E-15			
Meta-analysis EUR	Top 20% vs Rest of population		NA		1.53	0.06	1.37	1.71	1.4E-13			
N=44,958	Top 10% vs Rest of population				1.58	0.07	1.36	1.82	7.1E-10			
	Top 5% vs Rest of population				1.66	0.10	1.37	2.01	1.6E-07			
			African (AFR) ancestry									
	Top 40% vs Rest of population	4.45	3.38	1.07								
AncestryDNA AFR	Top 30% vs Rest of population	4.09	3.68	0.41								
N=1,629	Top 20% vs Rest of population	4.36	3.67	0.69	Number	of severe ca	ses too small	for analysis	(N<100)			
N-1,629	Top 10% vs Rest of population	2.50	3.95	-1.45								
	Top 5% vs Rest of population	2.44	3.88	-1.44								
	Top 40% vs Rest of population	5.65 (14/248)	7.80 (29/372)	-2.15								
UKB AFR	Top 30% vs Rest of population	5.95 (11/185)	7.36 (32/435)	-1.41								
N=620	Top 20% vs Rest of population	7.26 (9/124)	6.85 (34/496)	0.40	Numbe	r of severe ca	ases too small	for analysis	(N=43)			
N=020	Top 10% vs Rest of population	11.48 (7/61)	6.44 (36/559)	5.04	39							
	Top 5% vs Rest of population	9.68 (3/31)	6.79 (40/589)	2.89								
	Top 40% vs Rest of population	6.43 (9/140)	7.66 (16/209)	-1.23								
PMBB AFR	Top 30% vs Rest of population	6.67 (7/105)	7.38 (18/244)	-0.71								
N=349	Top 20% vs Rest of population	10.00 (7/70)	6.45 (18/279)	3.55	Numbe	r of severe ca	ases too small	for analysis	(N=25)			
11 579	Top 10% vs Rest of population	8.57 (3/35)	7.01 (22/314)	1.57								
	Top 5% vs Rest of population	5.56 (1/18)	7.25 (24/331)	-1.70								
		Admixed American	(AMR) and South Asian ((SAS) ancestries	S							
	Top 40% vs Rest of population	2.61	1.86	0.75								

AncestryDNA AMR N=3,752	Top 30% vs Rest of population	3.23	1.71	1.52	Number of severe cases too small for analysis (N<100)		
	Top 20% vs Rest of population	3.90	1.73	2.17			
	Top 10% vs Rest of population	4.26	1.93	2.33			
	Top 5% vs Rest of population	4.79	2.02	2.77			
UKB SAS N=760	Top 40% vs Rest of population	4.61 (14/304)	3.95 (18/456)	0.66			
	Top 30% vs Rest of population	4.82 (11/228)	3.95 (21/532)	0.88			
	Top 20% vs Rest of population	5.30 (8/151)	3.94 (24/609)	1.36	Number of severe cases too small for analysis (N=32)		
	Top 10% vs Rest of population	6.58 (5/76)	3.95 (27/684)	2.63			
	Top 5% vs Rest of population	7.89 (3/38)	4.02 (29/722)	3.88			

^{*} Logistic regression model adjusted for age, sex, age x sex, BMI, ancestry-informative PCs, REGENIE genome-wide predictor (to account for family structure) and clinical risk factors associated with risk of hospitalization and severe disease: chronic kidney disease, diabetes, immunosuppressive disease, chronic obstructive pulmonary disease or other chronic respiratory disease, cardiovascular disease, hyptertension (see methods for details)

Supplementary Table 20. Association between a 6-SNP genetic risk score (GRS) and risk of hospitalization and severe disease in individuals of European ancestry, after stratifying COVID-19 cases by pre-existing clinical risk factor status for severe COVID-19.

Population, total N COVID-19 cases	Clinical Risk Level	N COVID-19 cases	Risk among COVID-19 cases (N positive and [hospitalized or severe] / N positive) x 100		Unadjusted Risk	Adjusted Odds Ratio**								
			Top 10% GRS	Rest of Population	Difference	Estimate	SE	LCI	UCI	P-value				
Risk of hospitalization														
AncestryDNA EUR	Lower	12,464	4.07	2.39	1.69	1.70	0.16	1.25	2.31	6.8E-04				
N=25,353	High	12,889	14.14	8.49	5.64	1.80	0.09	1.51	2.15	5.3E-11				
UKB EUR	Lower	8,912	17.86 (152/851)	15.72 (1267/8061)	2.14	1.21	0.10	1.00	1.46	0.051				
N=14,320	High	5,408	47.58 (246/517)	45.25 (2213/4891)	2.34	1.09	0.10	0.91	1.32	0.343				
GHS EUR	Lower	1,537	5.48 (8/146)	2.95 (41/1391)	2.53	1.98	0.42	0.87	4.53	0.105				
N=5,285	High	3,748	23.24 (89/383)	18.96 (638/3365)	4.28	1.21	0.14	0.92	1.59	0.171				
Meta-analysis EUR	Lower	22,913			1.35	0.08	1.15	1.58	2.1E-04					
N=44,958	High	22,045			1.39	0.06	1.23	1.56	3.7E-08					
Risk of severe disease														
AncestryDNA EUR	Lower	12,464	1.64	0.78	0.87	2.04	0.25	1.25	3.33	4.2E-03				
N=25,353	High	12,889	7.15	4.04	3.11	1.70	0.13	1.33	2.17	2.5E-05				
UKB EUR	Lower	8,912	3.41 (29/851)	2.25 (181/8061)	1.16	1.58	0.21	1.05	2.37	0.027				
N=14,320	High	5,408	19.73 (102/517)	13.06 (639/4891)	6.66	1.60	0.12	1.25	2.03	1.5E-04				
Meta-analysis EUR	Lower	21,376	NA			1.75	0.16	1.28	2.40	4.2E-04				
N=39,673	High	18,297				1.65	0.09	1.39	1.96	1.5E-08				

^{*} High clinical risk included indiviiduals with any of the following criteria: age≥65, BMI≥35, chronic kidney disease, diabetes, immunosuppressive disease, or age ≥55 and presence of chronic obstructive pulmonary disease, cardiovascular disease, or hypertension (see methods for details).

^{**} Logistic regression model adjusted for sex, ancestry-informative PCs and REGENIE genome-wide predictor to account for family structure.